zidovudine has been researched along with efavirenz in 309 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 15 (4.85) | 18.2507 |
2000's | 116 (37.54) | 29.6817 |
2010's | 155 (50.16) | 24.3611 |
2020's | 23 (7.44) | 2.80 |
Authors | Studies |
---|---|
Aiello, F; Armaroli, S; Bergamini, A; Bolacchi, F; Bongiovanni, B; Caccia, S; Campiani, G; Capozzi, M; Coletta, M; Fabbrini, M; Garofalo, A; Greco, G; Guiso, G; Maga, G; Marini, S; Morelli, E; Nacci, V; Novellino, E; Ramunno, A; Spadari, S; Ventura, L | 1 |
Singh, SK; Yadav, A | 1 |
Bergamini, A; Butini, S; Campiani, G; Catalanotti, B; Coletta, M; De Angelis, M; Fattorusso, C; Fiorini, I; Gemma, S; Greco, G; Huleatt, P; Maga, G; Marini, S; Nacci, V; Novellino, E; Persico, M; Ramunno, A; Rodriquez, M; Spadari, S | 1 |
Alongi, M; Armand-Ugón, M; Bernardini, C; Botta, M; Cancio, R; Carmi, C; Clotet-Codina, I; Corelli, F; Crespan, E; Esté, JA; Maga, G; Manetti, F; Massa, S; Mugnaini, C; Petricci, E; Togninelli, A | 1 |
Botta, M; Cancio, R; Clotet-Codina, I; Corelli, F; Esté, JA; Maga, G; Manetti, F; Mugnaini, C | 1 |
Buckheit, RW; Cho, EH; Chung, SG; Hartman, TL; Watson, KM | 1 |
Alongi, M; Angeli, L; Armand-Ugón, M; Bellucci, L; Bernardini, C; Botta, M; Brizzi, A; Clotet-Codina, I; Corelli, F; Esté, JA; Facchini, M; Gevariya, H; Maga, G; Manetti, F; Massa, S; Mugnaini, C; Samuele, A; Tafi, A; Togninelli, A | 1 |
Balzarini, J; Chen, FE; De Clercq, E; Pannecouque, C; Wang, YP | 1 |
Colonno, R; Dicker, I; Fan, L; Gali, V; Higley, H; Krystal, M; Lin, PF; Nowicka-Sans, B; Parkin, N; Tenney, D; Terry, B; Wang, C; Zhang, S | 1 |
Barreca, ML; Benkestock, K; Chimirri, A; Christ, F; De Luca, L; Debyser, Z; Eneroth, A; Ferro, S; Hombrouck, A; Johansson, NG; Michiels, M; Noppe, W; Sahlberg, BL; Van Remoortel, B; Vrang, L; Witvrouw, M | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Cao, Y; De Clercq, E; Liu, X; Pannecouque, C; Wang, Y; Zhan, P | 1 |
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
Bergamini, A; Borrelli, G; Brindisi, M; Butini, S; Campiani, G; Coccone, SS; Cosconati, S; Di Mattia, M; Galletti, B; Gemma, S; Giorgi, G; Lalli, S; Maga, G; Marinelli, L; Novellino, E; Ramunno, A; Samuele, A; Zanoli, S | 1 |
Bachmann, MH; Fessel, WJ; Kagan, RM; Mitsuya, Y; Shafer, RW; Shahriar, R; Varghese, V | 1 |
Cao, Y; Guo, Y; Sun, Y; Xu, B; Yu, T | 1 |
De Clercq, E; Fang, Z; Li, Z; Liu, X; Pannecouque, C; Zhan, P | 1 |
Clercq, ED; Fang, Z; Li, Z; Liu, X; Pannecouque, C; Zhan, P; Zhu, J | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
Fransen, S; Gupta, S; Huang, W; Paxinos, EE; Petropoulos, CJ; Stawiski, E | 1 |
Corbau, R; Fishburn, L; Irving, S; Knöchel, T; Martin, A; Mori, J; Mowbray, C; Panton, W; Perros, M; Phillips, C; Ringrose, H; Smith-Burchnell, C; Thornberry, A; Westby, M; Wood, A | 1 |
Engelman, A; Haim, H; Koh, Y | 1 |
Cao, YL; Chen, CX; Fang, PL; Gong, NB; Guo, Y; Liu, HY; Liu, SC; Lü, Y; Pan, LL; Yan, H; Zhong, HM | 1 |
De Clercq, E; Ge, W; Jiang, Y; Li, Z; Liu, X; Pannecouque, C; Wu, J; Zhan, P; Zhang, J | 1 |
Chang, J; Chen, CH; Guo, X; Hu, W; Lee, KH; Pan, Z; Qian, K; Tao, L; Wang, Q; Wang, S | 1 |
Balzarini, J; Chen, FE; De Clercq, E; Gu, SX; He, QQ; Ma, XD; Pannecouque, C; Yang, SQ | 1 |
Chen, W; Chen, X; De Clercq, E; Li, D; Li, X; Liu, X; Pannecouque, C; Tian, Y; Zhan, P | 1 |
Balzarini, J; Chen, FE; Clercq, ED; Dai, HF; Gu, SX; He, QQ; Ma, XD; Pannecouque, C; Yang, SQ | 1 |
Hamburger, M; Hamy, F; Klimkait, T; Louvel, S; Mojarrab, M; Potterat, O; Sanglier, JJ; Vidal, V | 1 |
Balzarini, J; Chen, X; De Clercq, E; Liu, X; Pannecouque, C; Zhan, P | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Balzarini, J; Chen, FE; De Clercq, E; Gu, SX; He, QQ; Li, ZM; Ma, XD; Pannecouque, C; Yang, SQ | 1 |
Chen, X; Cheng, Z; De Clercq, E; Liu, X; Meng, C; Pannecouque, C; Shao, S; Zhan, P | 1 |
Borrell, JI; Clotet, B; Esté, JA; Giménez, L; Gonzalo, E; Pascual, R; Pettersson, S; Puig-de-la-Bellacasa, R; Teixidó, J | 1 |
Brancale, A; Clotet, B; Coluccia, A; Cosconati, S; Esté, JA; Famiglini, V; Gonzalez, E; La Regina, G; Maga, G; Novellino, E; Piscitelli, F; Samuele, A; Schols, D; Silvestri, R | 1 |
Balzarini, J; Chen, X; De Clercq, E; Li, D; Li, X; Liu, H; Liu, X; Pannecouque, C; Wang, L; Zhan, P | 1 |
Chen, W; Chen, X; De Clercq, E; Li, X; Li, Z; Liu, X; Pannecouque, C; Tian, Y; Zhan, P | 1 |
Chen, W; Chen, X; Clercq, ED; Li, X; Li, Z; Liu, X; Pannecouque, C; Tian, Y; Zhan, P | 1 |
Chen, FE; Daelemans, D; De Clercq, E; Liu, Y; Ma, XD; Pannecouque, C; Yang, S | 1 |
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Balzarini, J; Chen, FE; Chen, WX; Daelemans, D; De Clercq, E; He, QQ; Pannecouque, C; Wu, HQ; Yan, ZH | 1 |
Balzarini, J; Chen, X; De Clercq, E; Li, Z; Liu, H; Liu, X; Pannecouque, C; Xie, Z; Zhan, P; Zhang, L; Zhao, T | 1 |
Ba, M; Gu, Q; Guo, Y; Li, D; Li, G; Li, L; Ma, X; Zhu, T | 1 |
De Clercq, E; Li, Z; Liu, H; Liu, X; Pannecouque, C; Wang, J; Zhan, P | 1 |
Chen, FE; Chen, WX; De Clercq, E; He, QQ; Huang, XY; Pannecouque, C; Wu, HQ; Yan, ZH | 1 |
Badia, R; Brancale, A; Cirilli, R; Clotet, B; Coluccia, A; Crespan, E; Esté, JA; Famiglini, V; La Regina, G; Maga, G; Novellino, E; Pelliccia, S; Silvestri, R | 1 |
Chen, FE; Chen, WX; De Clercq, E; He, QQ; Pannecouque, C; Piao, HR; Wu, HQ; Wu, Y; Yan, ZH | 1 |
Collu, G; Giliberti, G; La Colla, P; Loddo, R; Loksha, YM; Pedersen, EB; Sanna, G | 1 |
Balzarini, J; Chen, F; Chen, W; De Clercq, E; Liu, Y; Meng, G; Pannecouque, C; Zheng, A | 1 |
Ba, M; Cao, Y; Guo, C; Guo, Y; He, R; Li, Z; Liang, Y; Tang, C; Xu, Z; Yang, Y; Zhang, X; Zhou, H; Zhu, L | 1 |
Chen, W; De Clercq, E; Liu, X; Liu, Z; Pannecouque, C; Zhan, P | 1 |
Chen, FE; Chen, WX; Daelemans, D; De Clercq, E; He, QQ; Pannecouque, C; Wu, HQ; Yao, J | 1 |
Balzarini, J; Chen, W; De Clercq, E; Fu, L; Huang, B; Li, C; Liu, H; Liu, T; Liu, X; Pannecouque, C; Sun, Y; Yu, M; Zhan, P | 1 |
Chen, W; De Clercq, E; Fu, L; Huang, B; Li, C; Li, X; Liang, X; Liu, H; Liu, T; Liu, X; Pannecouque, C; Sun, Y; Zhan, P | 1 |
Chen, FE; Chen, WX; Daelemans, D; De Clercq, E; He, QQ; Mao, TQ; Pannecouque, C; Tang, GF; Wan, ZY | 1 |
Bond, VC; Cox, BD; Huang, MB; Krystal, M; Lee, S; Li, Z; Liotta, DC; Prosser, AR; Snyder, JP; Sun, Y; Wilson, LJ | 1 |
Chen, W; Daelemans, D; De Clercq, E; Huang, B; Kang, D; Li, X; Liu, X; Liu, Z; Lu, X; Pannecouque, C; Yang, J; Zhan, P | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Chen, X; Daelemans, D; De Clercq, E; Huang, B; Kang, D; Li, W; Liu, X; Meng, Q; Pannecouque, C; Zhan, P | 1 |
Li, X; Li, YG; Pang, W; Shen, YM; Wang, P; Wang, RR; Wu, JF; Yang, L; Yang, LM; Zheng, YT | 1 |
Chizhov, AO; Geisman, AN; Khandazhinskaya, AL; Kochetkov, SN; Naesens, L; Novikov, MS; Ozerov, AA; Pannecouque, C; Seley-Radtke, KL; Valuev-Elliston, VT | 1 |
Buckheit, RW; Cushman, M; Hartman, TL; Hoshi, A; Okazaki, M; Pannecouque, C; Sakamoto, T; Takayama, J; Xuan, M | 1 |
Chen, W; Daelemans, D; De Clercq, E; Huang, B; Liu, X; Pannecouque, C; Yang, J; Zhan, P | 1 |
Daelemans, D; De Clercq, E; Ding, X; Fang, Z; Huang, B; Kang, D; Li, Z; Liu, X; Lu, X; Pannecouque, C; Xu, H; Zhan, P; Zhang, H; Zhou, Z | 1 |
Ashok, P; Chander, S; Sankaranarayanan, M; Wang, P; Yang, LM; Zheng, YT | 1 |
De Clercq, E; Huo, Z; Kang, D; Liu, H; Liu, X; Pannecouque, C; Tian, Y; Zhan, P; Zhang, H; Zhou, Z | 1 |
Gu, SX; Ju, XL; Li, TT; Lu, HH; Pannecouque, C; Xiao, T; Xue, P; Zhang, X; Zheng, XJ; Zhu, YY | 1 |
Gu, SX; Ju, XL; Liu, GY; Lu, HH; Pannecouque, C; Xue, P; Zhang, XL; Zheng, XJ; Zhu, YY | 1 |
Daelemans, D; De Clercq, E; Ding, X; Fang, Z; Huang, B; Huo, Z; Kang, D; Liu, X; Lu, X; Meng, Q; Pannecouque, C; Tian, Y; Wu, G; Xu, H; Yu, Z; Zhan, P; Zhang, H; Zhou, Z | 1 |
Badia, R; Brambilla, A; Brancale, A; Catalano, M; Cirilli, R; Coluccia, A; Crespan, E; Esté, JA; Famiglini, V; Formica, FR; La Regina, G; Limatola, C; Maga, G; Masci, D; Novellino, E; Riveira-Muñoz, E; Silvestri, R | 1 |
Daelemans, D; De Clercq, E; Huang, B; Kang, D; Liu, J; Liu, X; Liu, Z; Pannecouque, C; Tian, Y; Zhan, P | 1 |
Ba, M; Dai, J; Guo, J; Guo, Y; Liu, X; Tao, X; Yu, L; Zhang, D; Zhang, M | 1 |
Chen, F; De Clercq, E; Jin, K; Meng, G; Pannecouque, C; Yin, H | 1 |
Daelemans, D; De Clercq, E; Gao, P; Kang, D; Liu, X; Lu, X; Pannecouque, C; Yang, J; Zhan, P | 1 |
Chen, CH; Daelemans, D; De Clercq, E; Huang, B; Kang, D; Lee, KH; Liu, J; Liu, X; Liu, Z; Pannecouque, C; Tian, Y; Zhan, P; Zhang, H | 1 |
Daelemans, D; De Clercq, E; Desta, S; Ding, X; Huo, Z; Jing, L; Kang, D; Liu, X; Pannecouque, C; Wang, Z; Wu, G; Zhan, P; Zhang, H; Zhou, Z; Zuo, X | 1 |
Clercq, E; Daelemans, D; Ding, X; Feng, D; Guma, S; Huang, B; Huo, Z; Jing, L; Kang, D; Liu, X; Luo, W; Pannecouque, C; Wang, Z; Wu, G; Zhan, P; Zhang, H; Zhang, J; Zhao, T; Zhou, Z; Zuo, X | 1 |
Bhansali, S; Bhosale, R; Gawali, R; Mitra, D; Sarkar, D; Trivedi, J | 1 |
Byrareddy, SN; Kongsted, J; Kramer, VG; Kurup, S; Liu, X; Namasivayam, V; Vanangamudi, M; Zhan, P | 1 |
Chen, FE; Gu, SX; Liu, GY; Meng, G; Pannecouque, C; Tang, JF; Wu, FS; Xiao, T; Xu, ZQ; Zhu, YY | 1 |
Armijos Rivera, JI; Badia, R; Brambilla, A; Catalano, M; Cinquina, E; Coluccia, A; Crespan, E; Esté, JA; Falasca, F; La Regina, G; Limatola, C; Maga, G; Masci, D; Nalli, M; Riveira-Muñoz, E; Silvestri, R; Turriziani, O | 1 |
Cherukupalli, S; De Clercq, E; Feng, D; Fu, Z; Jiang, X; Kang, D; Liu, X; Pannecouque, C; Wang, Z; Zhan, P | 1 |
De Clercq, E; Huang, B; Jiang, X; Kang, D; Li, J; Liu, X; Olotu, FA; Pannecouque, C; Soliman, MES; Wang, Z; Zhan, P | 1 |
Chen, CH; De Clercq, E; Feng, D; Jing, L; Kang, D; Lee, KH; Lin, H; Liu, X; Olotu, FA; Pannecouque, C; Soliman, M; Zhan, P; Zuo, X | 1 |
De Clercq, E; Gao, P; Liu, X; Pannecouque, C; Song, S; Sun, L; Wang, Z; Zhan, P; Zhang, J | 1 |
Cherukupalli, S; De Clercq, E; Fu, Z; Gao, S; Kang, D; Liu, X; Pannecouque, C; Sun, L; Zhan, P; Zhang, T; Zhou, Z | 1 |
Chen, FE; De Clercq, E; Jin, X; Pannecouque, C; Piao, HR; Zhuang, C | 1 |
Cheng, Y; De Clercq, E; Gao, P; Gao, S; Kang, D; Liu, X; Pannecouque, C; Song, L; Song, S; Sun, L; Xu, S; Zhan, P; Zhao, F | 1 |
Chen, FE; Clercq, E; Hao, QQ; Ling, X; Pannecouque, C | 1 |
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Saag, MS; Schooley, RT | 1 |
Ahmad, M; Brennan, JM; Caliendo, AM; Fiske, WD; Flanigan, TP; Gormley, JM; Tashima, KT | 1 |
Temesgen, Z; Wright, AJ | 1 |
Farina, D; Johnson, P; Labriola, DF; Manion, DJ; Morales-Ramirez, J; Rachlis, A; Ruiz, NM; Skiest, D; Stanford, J; Staszewski, S; Stryker, R; Tashima, KT | 1 |
Staszewski, S | 1 |
Katlama, C | 1 |
Maga, G; Pregnolato, M; Salvetti, R; Spadari, S; Ubiali, D | 1 |
Casado, JL; Moreno, S | 1 |
Bower, M; Gazzard, BG; Mandalia, S; Matthews, GV; Moyle, GJ; Nelson, M | 1 |
Albright, AV; Erickson-Viitanen, S; Frank, I; González-Scarano, F; O'Connor, M; Rayner, MM | 1 |
Gosselin, G; Hübscher, U; Maga, G; Pregnolato, M; Spadari, S; Ubiali, D | 1 |
Falkenberg, J; Gilden, D; Torres, G | 1 |
Hanna, L | 1 |
Bartlett, JG; del Rio, C | 1 |
Bickel, M; Jacobi, V; Rickerts, V; Staszewski, S; Tews, J | 1 |
Campelli, A; Indiveri, F; Murdaca, G; Puppo, F; Setti, M | 1 |
Craig, K | 1 |
Bettendorf, D; Bucy, RP; Chan, E; Evans, T; Gonzalez, CJ; Landay, AL; Phair, JP; Schmitz, JL; Schnizlein-Bick, CT; Spritzler, J; Squires, KE | 1 |
Alexander, C; Soldin, SJ; Ting, L; Volosov, A | 1 |
Diaz, B; Martín-Carbonero, L; Pérez-Olmeda, M; Soriano, V | 1 |
Brenner, B; Detorio, M; Loemba, H; Ma'ayan, S; Moisi, D; Oliveira, M; Parniak, MA; Spira, B; Wainberg, MA | 1 |
Flexner, C; Gandhi, R | 1 |
Chemlal, K; de Truchis, P; Devidas, A; Force, G; Mamet, JP; Mechali, D; Praindhui, D; Pulik, M; Rouveix, E; Welker, Y | 1 |
Atwine, D; Kebba, A; Kityo, C; Mwebaze, R; Nakityo, R; Peter, M | 1 |
Oka, S; Teruya, K | 1 |
Brault, C; Chennebault, JM; Loison, J; Payan, C; Peigne, M | 1 |
Labelle, C; Moreno, A; Samet, JH | 1 |
Becker, MI; D'Aquila, RT; De Gruttola, V; Delapenha, R; Dubé, MP; Fischl, MA; Gedeon, L; Hirsch, MS; Merigan, TC; Murphy, RL; Pettinelli, C; Pollard, RB; Robbins, GK; Shafer, RW; Smeaton, LM; Snyder, SW; van der Horst, C; Vella, S | 1 |
D'Aquila, RT; De Gruttola, V; Gripshover, BM; Haubrich, R; Hirsch, MS; Johnson, VA; Kaul, P; Martinez, AI; McCarty, SD; Merigan, TC; Morse, GD; Nokta, MA; Robbins, GK; Shafer, RW; Smeaton, LM; Snyder, SW; Swingle, M; Vella, S | 1 |
Feinberg, J | 2 |
Gazzard, BG; Gotch, F; Hand, J; Imami, N; Nelson, M; Pires, A; Portsmouth, S; Stebbing, J | 1 |
Boyle, BA | 1 |
Acosta, EP; Gulick, RM; Klingman, KL; Kuritzkes, DR; Lustgarten, S; Maher, WE; Meyer, WA; Murphy, RL; Pilcher, CD; Reichman, RC; Ribaudo, HJ; Schackman, BR; Shikuma, CM; Snyder, S; Squires, KE; Witt, MD | 1 |
Delfraissy, JF; Gatell, JM; Giordano, M; Jemsek, J; Lazzarin, A; Pokrovskiy, V; Powderly, WG; Rivero, A; Rozenbaum, W; Schrader, S; Sension, M; Squires, K; Thiry, A; Vibhagool, A | 1 |
De Luca, A; Di Giambenedetto, S | 1 |
Castillo, SA; DeJesus, E; Farthing, CF; Gough, K; Grinsztejn, B; Madison, SJ; McCarty, D; Schrader, SR; Sension, MG; Shortino, DD; Thomas, DA | 1 |
Maida, I; Nuñez, M; Soriano, V | 1 |
Agrawal, KC; Ali, M; Mondal, D; Pradhan, L | 1 |
Bonny, T; Brand, JD; Brothers, CH; Buendia, CB; Castillo, SA; DeJesus, E; Gerstoft, J; Hernandez, J; Herrera, G; Lanier, ER; Scott, TR; Teofilo, E | 1 |
Bower, M; Fisher, M; Gazzard, B; Johnson, M; Jones, R; Mandalia, S; Moyle, G; Nelson, M; Orkin, C; Stebbing, J | 1 |
Gerber, JG; Wyles, DL | 1 |
Cancio, R; Crespan, E; Hübscher, U; Locatelli, GA; Maga, G; Spadari, S | 1 |
del Rio, C | 1 |
Andréola, M; Cruchaga, C; Martínez-Irujo, JJ; Odriozola, L; Tarrago-Litvak, L | 1 |
Balakrishnan, P; Carpenter, CC; Cecelia, A; Flanigan, TP; Kumarasamy, N; Mayer, KH; Solomon, S; Vallabhaneni, S | 1 |
Gatanaga, H | 1 |
Andreoli, A; Bandelier, C; Bianchi-Demicheli, F; Damsa, C; Lazignac, C; Maris, S; Vidailhet, P | 1 |
Davis, EA; DeJesus, E; Hill-Zabala, C; Lang, J; Lanier, ER; Liao, Q; Markowitz, M; Shaefer, M | 1 |
Amel, EB; Amel, LO; Amine, SM; Asma, J; Fethi, T; Mohamed, C; Mounira, G; Taoufik, BC | 1 |
Barroso, PF; Boechat, LJ; Melo, MF; Schechter, M; Vettore, MV | 1 |
Billaud, E; Bugnon, F; Cua, E; Cuzin, L; Dellamonica, P; Delpierre, C; Massip, P; Pugliese, P; Raffi, F | 1 |
Bautista-Arredondo, S; Bertozzi, SM; Mane, A | 1 |
Nolan, D | 1 |
Arathoon, E; Arlotti, M; Giordano, M; Jemsek, JG; Noor, MA; Perez, C; Pokrovskiy, V; Soccodato, M; Sosa, N; Thiry, A | 1 |
Arribas, JR; Campo, RE; Cheng, AK; Chuck, S; DeJesus, E; Enejosa, J; Gallant, JE; Gazzard, B; Lu, B; McColl, D; Pozniak, AL; Toole, JJ | 1 |
Fisher, M; Gazzard, B; Higgs, C; Johnson, M; Mandalia, S; Moyle, G; Nelson, M; Teague, A | 1 |
De Nicola, M; Ghibelli, L; Lichtner, M; Mastroianni, CM; Mengoni, F; Rossi, R; Sauzullo, I; Vullo, V | 1 |
Acosta, EP; Bastow, B; Carlson, M; Gulick, RM; Klingman, KL; Koletar, SL; Kuritzkes, DR; Lalama, C; Meyer, WA; Murphy, RL; Pilcher, CD; Reichman, RC; Ribaudo, HJ; Schackman, BR; Schouten, J; Shikuma, CM; Squires, KE | 1 |
Brothers, CH; Castillo, SA; Hernandez, JE | 1 |
Mitsuya, H | 1 |
Arribas, JR; Campo, RE; Chen, SS; Cheng, AK; DeJesus, E; Enejosa, J; Gallant, JE; Gazzard, B; McColl, D; Pozniak, AL; Toole, JJ | 1 |
de Bethune, MP; Figueiredo, A; Mak, J; Moore, KL; Sluis-Cremer, N; Tachedjian, G | 1 |
Han, N; Lan, MD; Liu, ZY; Lu, LH; Wei, HS; Yao, J; Zhang, FJ; Zhao, HX | 1 |
Angeletti, C; Boumis, E; Chinello, P; Lisena, FP; Papetti, F; Petrosillo, N | 1 |
Bastow, B; Glesby, MJ; Gulick, RM; Kuritzkes, DR; Meyer, WA; Ribaudo, HJ; Shikuma, CM; Tashima, KT; Webb, N; Yang, Y | 1 |
Gulick, RM; Klingman, KL; Koletar, SL; Kuritzkes, DR; Meyer, WA; Reichman, R; Ribaudo, HJ; Riddler, SA; Santana, J; Shikuma, C; Squires, KE | 1 |
Teruya, K | 1 |
Dubé, MP; Grinspoon, SK; Komarow, L; Mulligan, K; Parker, RA; Robbins, GK; Roubenoff, R; Tebas, P | 1 |
Amorim, AP; Campos, CP; Custódio, FL; Ferrão, SB; Fonseca, BA; Gaspar, GG; Golin, NA; Marangoni, AT; Melo, Ld; Morejón, KM; Ponzi, CC; Santana, RC; Vanni, T | 1 |
Ansari, AW; Heiken, H; Schmidt, RE | 1 |
Bridges, AS; Cohen, MS; Corbett, AH; Dumond, JB; Jung, BH; Kashuba, AD; Patterson, KB; Rezk, NL; Stewart, PW; Yeh, RF | 1 |
Gulick, RM; Kuritzkes, DR; Ribaudo, HJ | 1 |
Arribas, JR; Campo, RE; Chen, SS; Cheng, AK; Dejesus, E; Enejosa, J; Gallant, JE; Gazzard, B; Holmes, CB; McColl, D; Pozniak, AL; Toole, JJ | 1 |
Easley, KA; Lennox, JL; Lu, C; Ofotokun, I; Smithson, SE | 1 |
Radzio, J; Sluis-Cremer, N | 1 |
Chaisson, RE; Charalambous, S; Churchyard, GJ; Fielding, KL; Grant, AD; Hoffmann, CJ; Innes, C; Sulkowski, MS; Thio, CL | 1 |
Asenjo, MA; Barrufet, P; Domingo, P; Gatell, JM; Gutiérrez, F; Knobel, H; Mallolas, J; Pedrol, E; Peñaranda, M; Peraire, J; Pich, J; Vidal, F | 1 |
Doerries, R; Drechsler, H; Gass, A; Hardmeier, M; Kuhle, J; Mehling, M; Ruegg, S | 1 |
Herrera, L; Moreno, S; Sánchez-de la Rosa, R | 1 |
Cheng, J; Han, N; Liu, YN; Liu, ZY; Wei, HS; Zhang, FJ; Zhao, HX; Zhao, Y | 1 |
Basseila, GB; Bokilo, AD; Dokekias, AE; Galiba, FO; Malanda, F; Nsitou, MB; Ntsimba, P | 1 |
Balakrishnan, P; Kumarasamy, N; Murugavel, KG; Priya, B; Saghayam, S; Shankar, EM; Solomon, S; Sundaram, M; Venkatesh, KK | 1 |
Bentata, M; Chêne, G; Collin, F; Garré, M; Goujard, C; Lafaurie, M; Leport, C; Levy, Y; Molina, JM | 1 |
Cotter, BR; Currier, JS; Dubé, MP; Fichtenbaum, CJ; Gerschenson, M; Komarow, L; Mitchell, CK; Murphy, RL; Parker, RA; Squires, K; Stein, JH; Torriani, FJ | 1 |
Amin, J; Avihingsanon, A; Bowden, S; Cooper, DA; Dore, GJ; Lewin, SR; Locarnini, S; Marks, P; Matthews, GV; Petcharapirat, P; Rerknimitr, R; Ruxrungtham, K; Sasadeusz, J | 1 |
Ajayi, SO; Akingbola, TS; Brown, BJ; Oladokun, R; Omigbodun, OO; Osinusi, K | 1 |
Angels Ribas, M; Asensi, V; Berenguer, J; Domingo, P; Gimeno, JL; González, J; Miralles, P; Pedrol, E; Pérez-Molina, JA; Ribera, E; Santamaría, JM; Santos, J; Terrón, JA | 1 |
Angel, JB; Fätkenheuer, G; Greaves, W; Hoffmann, C; Horst, H; Landovitz, RJ; Long, J; Opravil, M | 1 |
George, C; Jayakumar, B; Lal, L; Yesoda, A | 1 |
Bélanger, AS; Caron, P; Guillemette, C; Harvey, M; Mehlotra, RK; Zimmerman, PA | 1 |
Bernstein, BM; Brown, TT; da Silva, BA; King, MS; McComsey, GA; Qaqish, RB | 1 |
Cao, YL; Chen, H; Guo, Y; Li, SX | 1 |
Ebrahimi, R; Ewan, J; Fisher, M; Kingston, M; Liu, H; Moyle, GJ; Orkin, C; Reilly, G; Shahmanesh, M; Wilkins, E | 1 |
Arribas López, JR | 1 |
Dieng, AB; Diop, BM; Diop, SA; Diouf, A; Fall, MB; Lakh, A; Ndiaye, I; Niang, Kh; Seydi, M; Soumaré, M; Sow, A; Sow, PS; Tekpa, G | 1 |
Kongnyuy, EJ; Shang, J; Shey, M; Wiysonge, CS | 1 |
Cheng, AK; Enejosa, J; Margot, NA; McColl, DJ; Miller, MD | 1 |
Louie, M; Marfatia, S; Mear, I; Meunier, J; Regnault, A; Viala-Danten, M | 1 |
Asahchop, EL; Brenner, BG; Moisi, D; Ntemgwa, M; Toni, TA; Wainberg, MA | 1 |
Boothby, M; Gathercole, LL; McGee, KC; McTernan, PG; Nightingale, P; Shahmanesh, M; Shojaee-Moradie, F; Tomlinson, JW; Umpleby, AM | 1 |
Battegay, M; Bernasconi, E; Cavassini, M; Elzi, L; Furrer, H; Hirschel, B; Ledergerber, B; Marzolini, C; Vernazza, P; Weber, R | 1 |
Cooper, V; Fisher, M; Gellaitry, G; Horne, R; Lange, AC; Vrijens, B; White, D | 1 |
Clumeck, N; Coakley, E; Cooper, DA; Dejesus, E; Goodrich, J; Hackman, F; Heera, J; Horban, A; Ive, P; Mayer, H; Mingrone, H; Mohapi, L; Reeves, JD; Reyes-Teran, G; Saag, M; Sullivan, J; Tawadrous, M; Ting, N; Van Der Ryst, E; Walmsley, S; Westby, M | 1 |
Deshpande, A; Fleury, HJ; Jeannot, AC; Pinson, P; Schrive, MH; Wittkop, L | 1 |
Asboe, D; Dunn, D; Fearnhill, E; Gazzard, B; Pillay, D; Pozniak, A; Price, H | 1 |
Abzug, MJ; Brogly, SB; Conway, D; Cunningham, CK; Oleske, J; Sperling, RS; Spiegel, H; Van Dyke, RB; Watts, DH; Williams, PL | 1 |
Gerstoft, J; Hansen, AB; Nielsen, H; Obel, N; Pedersen, C | 1 |
Avihingsanon, A; Belloso, WH; Boesecke, C; Cooper, DA; Duncombe, C; Emery, S; Gazzard, B; Li, L; Molina, JM; Petoumenos, K; Puls, RL; Srasuebkul, P | 1 |
Castelnuovo, B; Kamya, MR; Kiragga, A; Manabe, Y | 1 |
Bachani, D; Chan, PL; Deshpande, A; Rajasekaran, S; Rewari, BB; Srikantiah, P | 1 |
Rutherford, GW; Siegfried, N; Spaulding, A | 1 |
Dhlomo, S; Emery, S; Grandits, G; Khabo, P; Khanyile, T; Komati, S; Magongoa, D; Naidoo, LC; Neaton, JD; Polis, M; Qolohle, D; Ratsela, A | 1 |
Delaporte, E; Diouf, A; Etard, JF; Girard, PM; Landman, R; Laurent, C; Molinari, N; Ndoye, I; Ngom Guèye, NF; Sow, PS; Tchatchueng Mbougua, JB | 1 |
Alvarez, SM; de Jesús Asencio Montiel, I; Flores, RA; Martínez, JG; Mata Marín, JA | 1 |
Cooper, V; Ewan, J; Fisher, M; Horne, R; Liu, HC; Moyle, GJ; Reilly, G | 1 |
Anh, DT; Bang, ND; Chau, NV; Chau, TT; Chinh, NT; de Jong, M; Dong, DT; Dung, NH; Dung, NT; Farrar, JJ; Hai, NN; Hien, NQ; Hien, TT; Lan, NN; Lan, NT; Mai, NT; Mai, PP; Minh, NH; Phu, NH; Quy, HT; Simmons, CP; Thai, PV; Thoa, NT; Tien, NA; Török, ME; Wolbers, M; Yen, NT | 1 |
Avancena, P; Hubbard, T; Kitchen, CM; Marsden, MD; Zack, JA | 1 |
Dia, AT; Diallo, PD; Gaye, AM; Sow, PG | 1 |
Claassen, M; Preiser, W; van der Merwe, L; van Zyl, GU; Zeier, M | 1 |
Calis, JC; de Wit, TF; Geelen, SP; Sigaloff, KC; van Vugt, M | 1 |
Cooper, DA; Duncombe, C; Emery, S; Gill, JM; Kerr, SJ; Li, PC; Puls, R; Taylor-Robinson, SD; Winston, A | 1 |
Beck-Sagué, CM; Fernandez, AD; Leonardo-Guerrero, J; Nicholas, SW; Roman-Pouriet, J; Schmidt, NC | 1 |
Al-Daghri, NM; Boothby, M; Das, S; Gathercole, LL; Harte, AL; McGee, KC; McTernan, PG; Nightingale, P; Shahmanesh, M; Shojaee-Moradie, F; Tomlinson, JW; Tripathi, G; Umpleby, AM | 1 |
Agu, KA; Akpoigbe, KJ; Badru, T; Chabikuli, O; Eluwa, GI; Hamelmann, C | 1 |
Arasteh, K; Boven, K; Crauwels, H; De Wet, J; Gathe, J; Gold, J; Hodder, S; Kumar, P; Mohapi, L; Short, W; Vanveggel, S | 1 |
Shah, I | 1 |
Jaye, A; Oko, F; Okomo, U; Peterson, I; Peterson, K; Togun, T; Townend, J | 1 |
Carda-Broch, S; Casas-Breva, I; Esteve-Romero, J; Peris-Vicente, J; Rambla-Alegre, M | 1 |
Côté, HC; Hukezalie, KR; Thumati, NR; Wong, JM | 1 |
Agbaji, O; Ekong, E; Graham, C; Hawkins, C; Idoko, J; Kanki, P; Meloni, S; Muazu, M; Murphy, R; Nimzing, L; Sankalé, JL; Thio, CL | 1 |
Bissek, AC; Defo, D; Kouotou, EA; Mboua, JB | 1 |
Larrechi, MS; Martí-Aluja, I; Ruisánchez, I | 1 |
Frenkel, L; Ton, Q | 1 |
Aebi-Popp, K; Gingelmaier, A; Hoesli, I; Lyons, F; Mulcahy, F; Rudin, C; Thorne, C | 1 |
Alobwede, SM; Kongnyuy, EJ; Shey, MS; Wiysonge, CS | 1 |
Arnett, DK; Bagchi, S; Chi, BH; Heimburger, DC; Kabagambe, EK; Kiage, JN; Koethe, JR; Nyirenda, CK; Wellons, MF | 1 |
Aguilar, A; De La Torre, J; Del Arco, A; García-Alegría, J; Olalla, J; Pombo, M; Prada, JL; Ruiz-Mateas, F; Urdiales, D | 1 |
Aghokeng, A; Belec, L; Bertagnolio, S; Bunupuradah, T; Burda, S; Cane, P; Cappelli, G; Charpentier, C; Dagnra, AY; de Wit, TF; Deshpande, AK; El-Katib, Z; Eshleman, SH; Fleury, HJ; Fokam, J; Ford, N; Gody, JC; Hamers, RL; Hawkins, CA; Holmes, S; Hosseinipour, MC; Jordan, MR; Kanki, PJ; Katzenstein, D; Koyalta, DD; Kumwenda, JJ; Lallemant, M; Lynen, L; Manosuthi, W; Marconi, VC; Margot, NA; Moussa, S; Ndung'u, T; Ngo-Giang-Huong, N; Nyambi, PN; Orrell, C; Peeters, M; Rhee, SY; Ruxrungtham, K; Schapiro, JM; Schuurman, R; Shafer, RW; Sigaloff, KC; Sirivichayakul, S; Smith, D; Stevens, W; Tang, MW; van Zyl, GU; Wallis, CL; Zolfo, M | 1 |
Boonsuk, S; Butchon, R; Chokephaibulkit, K; Kullert, N; Kulpeng, W; Phanuphak, N; Pilasant, S; Tantivess, S; Teerawattananon, Y; Tosanguan, K; Voramongkol, N; Werayingyong, P | 1 |
Bosco, O; Cruciani, M; Malena, M; Mengoli, C; Parisi, SG; Serpelloni, G | 1 |
Ampofo, WK; Barnor, JS; Brandful, JA; Ibe, S; Ishikawa, K; Nii-Trebi, NI; Ofori, SB; Sugiura, W; Yamaoka, S | 1 |
de Oliveira, T; Lessells, RJ; Manasa, J; McGrath, N; Naidu, KK; Newell, ML; Skingsley, A | 1 |
Aklillu, E; Gustafsson, LL; Kuteesa, RB; Mukonzo, JK; Nanzigu, S; Ogwal-Okeng, J; Owen, JS; Ross, C; Sewankambo, N; Thabane, L | 1 |
Choun, K; De Weggheleire, A; Lynen, L; Phirum, L; Thai, S; van Griensven, J | 1 |
Aghokeng, AF; Chia, JE; Delaporte, E; Einterz, E; Eymard-Duvernay, S; Molina, JM; Mpoudi-Ngole, E; Peeters, M; Taieb, F | 1 |
Crowe, SM; David, M; Gare, J; Hearps, AC; Imara, U; Kaima, P; Kelly-Hanku, A; Kombati, Z; Ryan, CE; Siba, PM; Timbi, D | 1 |
Arribas, J; Deckx, H; Duiculescu, D; Florence, E; Hung, CC; Sension, M; Stevens, M; Tebas, P; Vanveggel, S; Wilkin, T | 1 |
Brown, LA; Ferrell, D; Giunta, B; Jin, J; Obregon, D; Sadic, E; Smith, AJ; Tan, J | 1 |
Holla, P; Jameel, S; Munshi, SU; Panda, H; Rewari, BB | 1 |
Gui, T; Guo, W; Jia, L; Jiao, L; Li, H; Li, J; Li, L; Liu, S; Liu, Y; Zhuang, D | 1 |
Berendes, S; Campbell, TB; Cardoso, SW; Christian, P; Gupta, A; Gupte, N; Kanyama, C; Lama, JR; Mwelase, N; Pillay, S; Riviere, C; Samaneka, W; Semba, RD; Shivakoti, R; Sugandhavesa, P; Tang, AM; Yang, WT | 1 |
Bader, J; Glass, TR; Klimkait, T; Labhardt, ND; Lejone, TI; Puga, D; Ringera, I | 1 |
Fan, P; Li, J; Li, N; Liang, Y; Ma, Y; Sun, D; Wang, Z; Yang, W; Zhu, Q | 1 |
Aris, E; Baernighausen, T; Chalamilla, G; Fawzi, W; Hertzmark, E; Jackson, E; Machumi, L; Muya, A; Mwanyika-Sando, M; Sando, D; Spiegelman, D | 1 |
Avi, R; Huik, K; Jõgeda, EL; Kallas, E; Karki, T; Lutsar, I; Margus, T; Pauskar, M | 1 |
Antony, J; Arumugam, K; D'Souza, G; De Costa, A; Kumar, DS; Kumarasamy, N; Poongulali, S; Rewari, BB; Shastri, S; Shet, A | 1 |
Abongomera, G; Asiimwe, A; Burger, D; Chabala, C; Chintu, C; Cook, AD; Gibb, DM; Kekitiinwa, A; Kenny, J; Kityo, C; Klein, N; McIlleron, H; Mirembe, G; Mulenga, V; Musiime, V; Owen-Powell, E; Thomason, MJ; Walker, AS | 1 |
Fujii, N; Kaku, M; Kawaji, K; Kodama, EN; Miyamoto, F; Oishi, S | 1 |
Cai, W; Caughey, B; Chung, C; Dai, Z; Hu, F; Lan, Y; Li, L; Tang, X; Zhang, K | 1 |
Fu, LC; Lu, ZZ; Ma, JB; Song, C; Su, QJ; Tang, DH | 1 |
Aklillu, E; Bisaso, RK; Gustafsson, LL; Mukonzo, JK; Ogwal-Okeng, J; Owen, JS | 1 |
Amaral, E; Bahamondes, L; Bahamondes, MV; Brito, MB; Duarte, G; Ferriani, RA; Prandini, TR; Quintana, SM; Ragazini, CS; Vieira, CS | 1 |
Alves, LDS; Nadvorny, D; Rolim-Neto, PJ; Soares, MFR; Soares-Sobrinho, JL | 1 |
Belyhun, Y; Liebert, UG; Maier, M | 1 |
Birbal, S; Dheda, M; Ojewole, E; Oosthuizen, F | 1 |
Abach, J; Abongomera, G; Chabala, C; Colebunders, R; Cook, A; Gibb, DM; Kekitiinwa, A; Kityo, C; Lamorde, M; Mulenga, V; Musiime, V; Thomason, M; Walker, AS | 1 |
Brophy, JC; Chan, AK; Hawkes, MT; Mateyu, G; Mwinjiwa, E; Sodhi, SK | 1 |
Asari, V; Baxter, C; Garrett, N; Grobler, A; Karim, QA; Karim, SSA; Majola, N; Naicker, N; Naidoo, A; Werner, L | 1 |
Kondapi, AK; Kumar, P; Lakshmi, YS | 1 |
Boulle, A; Cohen, K; Davies, MA; de Waal, R; Fortuin-de Smidt, M; Igumbor, EU; Maartens, G; Stinson, K; Technau, KG | 1 |
Badal-Faesen, S; Brown, TT; Campbell, TB; Cardoso, SW; Erlandson, KM; Fiorillo, SP; Hakim, J; Kumarasamy, N; Kumwenda, J; Lalloo, U; Riviere, C; Sanchez, J | 1 |
Awoke, T; Birlie, B; Braekers, R; Kasim, A; Shkedy, Z | 1 |
Barrow, G; Camacho, R; Carmona, S; Grant, PM; Gupta, RK; Hamers, RL; Harrigan, PR; Jordan, MR; Kantor, R; Katzenstein, DA; Kuritzkes, DR; Maldarelli, F; Otelea, D; Paredes, R; Schapiro, JM; Shafer, RW; Tzou, PL; van Zyl, G; Wallis, CL | 1 |
Andolina, A; Carbone, A; Castagna, A; Franzin, M; Galizzi, N; Galli, L; Gianotti, N; Lazzarin, A; Merli, M; Muccini, C; Oltolini, C; Poli, A; Spagnuolo, V; Tadini, P | 1 |
Brambilla, D; Ceffa, S; De Luca, A; Liotta, G; Luhanga, R; Magid, NA; Mancinelli, S; Marazzi, MC; Palombi, L; Sidumo, ZJ; Zanelli, G | 1 |
Emanuel, K; Fox, HS; Lamberty, BG; Morsey, B; Stauch, KL | 1 |
Abalem, MF; Carricondo, PC; Rao, RC | 1 |
Chen, X; Fairley, CK; He, J; Jing, J; Mao, L; Sasadeusz, J; Su, S; Wei, X; Zeng, H; Zhang, L | 1 |
Cuong, DD; Dung, NT; Dung, NTH; Haneuse, S; Kinh, NV; Matsumoto, S; Oka, S; Tanuma, J; Thuy, PTT; Trung, NV; Vu, TV | 1 |
Ahmadi, NE; Ahsani-Nasab, S; Bayanolhagh, S; Esmaeilzadeh, A; Lolaie, M; Moallemi, S; Mohraz, M; Narouei, A; Sadeghi, L; SeyedAlinaghi, S; Tabatabai, RA | 1 |
Awodele, O; Oshikoya, KA; Popoola, TD | 1 |
Castelnuovo, B; Gonza, P; Kambugu, A; Kiragga, AN; Mbabazi, O; Mubiru, F; Musomba, R; Ratanshi, RP | 1 |
Bourrel, R; Lapeyre-Mestre, M; Montastruc, JL; Rwagitinywa, J; Sommet, A | 1 |
Antony, J; Ashoor, HM; Blondal, E; Finkelstein, Y; Ghassemi, M; Gough, K; Hemmelgarn, BR; Hutton, B; Ivory, JD; Khan, PA; Lillie, E; Straus, SE; Tricco, AC; Vafaei, A; Veroniki, AA | 1 |
Chu, L; Deng, H; Duan, C; Li, X; Qiao, S; Shen, Z; Wu, Y; Xie, Y; Yang, H; Yang, J; Zhang, Q | 1 |
Mugusi, S; Ngaimisi, E; Sasi, P; Sungi, SS; Ulenga, N | 1 |
Chendi, BH; Eyoh, A; Ikomey, GM; Jacobs, GB; Lyonga, E; Mesembe, M; Okomo Assoumou, MC; Yekwa, EL | 1 |
Huang, JP; Huang, WH; Luo, SD; Luo, XL; Mo, LD; Ni, ZY; Su, GS; Su, HZ; Wu, JY | 1 |
Adebisi, SA; Adedeji, NO; Adedeji, TA | 1 |
Chen, IT; Chen, JK; Chen, YS; Lee, SS; Sy, CL; Tsai, HC; Tseng, YT; Weng, YW; Wu, KS | 1 |
Bela, B; Ibrahim, F; Kusumaningrum, A; Yunihastuti, E | 1 |
Chadwick, EG; Correia, KF; Crowell, CS; DiPerna, A; Hazra, R; Seage, GR; Smith, R; Van Dyke, RB; Williams, PL; Yildirim, C | 1 |
George, PE; Mercedes, R; Nabukeera-Barungi, N; Otto, SBJ | 1 |
Arraes, LC; Brandão, LAC; Carvalho-Silva, WHV; Coelho, AVC; Crovella, S; Guimarães, RL; Moura, RR; Valeriano, JJLS | 1 |
Jiang, F; Lu, Z; Su, Q; Tang, Y; Wei, S; Zhou, Z | 1 |
Azmi, M; Baber, ZU; Badlani, S; Dodani, SK; Nasim, A; Sheerani, M | 1 |
Anthony, P; Best, BM; Cahn, P; Chakhtoura, N; Chokephaibulkit, K; Cressey, TR; de Lourdes B Teixeira, M; Essack, Z; Frenkel, LM; Fuller, TL; Gouvèa, MIS; Hennessy, R; João, EC; Laimon, L; Mathiba, R; Mirochnick, M; Mmbaga, BT; Moreira, LF; Morrison, RL; Ngocho, JS; Njau, BN; Pilotto, JHS; Prommas, S; Rolon, MJ; Shapiro, DE; Siberry, GK; Violari, A; Werarak, P | 1 |
Abdool Karim, Q; Dawood, H; Mansoor, LE; Matten, D; Naicker, CL; Naidoo, K; Singo, D; Williamson, C | 1 |
Jianwei, L; Menghua, W; Qinwei, Y; Xin, Z; Yu, Z | 1 |
Benamor Teixeira, ML; Chakhtoura, N; Coombs, RW; Frenkel, LM; Fuller, TL; Gouvêa, MI; Hennessey, R; João, EC; Mirochnick, M; Morrison, RL; Shapiro, DE; Whitson, K | 1 |
Borger, P; Buzdin, AA; Clavien, PA; Schneider, MA; Weber, A | 1 |
Abrams, EJ; Bonner, LB; Geffner, ME; Gerschenson, M; Jao, J; Kgole, S; Kurland, IJ; Legbedze, J; Makhema, J; Masasa, G; Mmalane, M; Mmasa, KN; Mohammed, T; Moyo, S; Powis, KM; Sun, S | 1 |
18 review(s) available for zidovudine and efavirenz
Article | Year |
---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1998 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
Review of NNRTIs: 'today and tomorrow'.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Oxazines; Reverse Transcriptase Inhibitors; Zidovudine | 1999 |
[Antiretrovirals].
Topics: Acidosis, Lactic; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Hemophilia A; Hemorrhage; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Indinavir; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2003 |
The continuing evolution of HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Delayed-Action Preparations; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Monitoring; Emtricitabine; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyridines; Randomized Controlled Trials as Topic; Stavudine; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2003 |
Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Cardiovascular Diseases; Cyclopropanes; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Metabolic Syndrome; Nevirapine; Oxazines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Risk Factors; Stavudine; Zidovudine | 2005 |
[Progress in AIDS therapy].
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Design; Drug Resistance, Viral; HIV Integrase Inhibitors; Humans; Imidazoles; Oxazines; Protease Inhibitors; Reverse Transcriptase Inhibitors; Sulfoxides; Zidovudine | 2006 |
[Antiretrovirals].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Prescriptions; Drug Therapy, Combination; Humans; Lopinavir; Protease Inhibitors; Pyrimidinones; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2007 |
[The "induction-maintenance" strategy].
Topics: Adipose Tissue; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Virus Replication; Zidovudine | 2008 |
A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Combinations; HIV Infections; Humans; Lamivudine; Nelfinavir; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic; Zidovudine | 2009 |
Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2010 |
HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review.
Topics: Adolescent; Africa; Alkynes; Anti-HIV Agents; Asia; Benzoxazines; Child; Child, Preschool; Cross-Sectional Studies; Cyclopropanes; Developing Countries; Drug Resistance, Viral; Female; Health Resources; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Latin America; Lopinavir; Male; Mutation; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Treatment Failure; Viral Load; Zidovudine | 2011 |
HIV drug resistance in mothers and infants following use of antiretrovirals to prevent mother-to-child transmission.
Topics: Alkynes; Anti-HIV Agents; Aptamers, Nucleotide; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Developing Countries; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Mothers; Nevirapine; Point Mutation; Pregnancy; Pregnancy Complications, Infectious; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Sentinel Surveillance; Sequence Analysis, DNA; Viral Load; Zidovudine | 2013 |
Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Nelfinavir; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic; Zidovudine | 2013 |
Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lipids; Maintenance Chemotherapy; Middle Aged; Nevirapine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Failure; Viral Load; Young Adult; Zidovudine | 2013 |
Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs.
Topics: Abnormalities, Drug-Induced; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Congenital Abnormalities; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Infant, Low Birth Weight; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Network Meta-Analysis; Nevirapine; Perinatal Care; Pregnancy; Pregnancy Complications, Infectious; Stavudine; Stillbirth; Zidovudine | 2018 |
65 trial(s) available for zidovudine and efavirenz
Article | Year |
---|---|
Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Oxazines; Viral Load; Zidovudine | 1999 |
Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 1999 |
Update on study 006--EFV + AZT + 3TC versus the current 'standard of care' IDV + AZT + 3TC.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Humans; Indinavir; Lamivudine; Lipid Metabolism; Oxazines; Viral Load; Zidovudine | 1999 |
Efavirenz shows promising results.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Oxazines; Reverse Transcriptase Inhibitors; Zidovudine | 1998 |
Sustiva added to three-drug combination.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zidovudine | 1998 |
Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antigens, CD; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Cyclopropanes; Didanosine; Dideoxynucleosides; Double-Blind Method; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2002 |
Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne.
Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; France; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2002 |
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Oxazines; RNA, Viral; Stavudine; Time Factors; Treatment Failure; Zidovudine | 2003 |
Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nelfinavir; Oxazines; Stavudine; Time Factors; Treatment Failure; Zidovudine | 2003 |
Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Trizivir vs. efavirenz: results from ACTG 5095.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Oxazines; Placebos; Viral Load; Zidovudine | 2003 |
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
Topics: Adult; Aged; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nucleosides; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 2004 |
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Oxazines; Pyridines; RNA, Viral; Zidovudine | 2004 |
Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 2004 |
Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; RNA, Viral; Zidovudine | 2004 |
New once-daily HIV combination better tolerated.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Oxazines; Tenofovir; Zidovudine | 2004 |
A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study).
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Viral Load; Zidovudine | 2005 |
Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Patient Compliance; RNA, Viral; Zidovudine | 2005 |
Effects on immunological and virological outcome of patients using one protease inhibitor or one non-nucleoside reverse transcriptase inhibitor in a triple antiretroviral therapy: normal clinical practice versus clinical trial findings.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Male; Oxazines; Retrospective Studies; Treatment Outcome; Tunisia; Viremia; Zidovudine | 2005 |
Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients.
Topics: Adiposity; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Oligopeptides; Oxazines; Pyridines; Zidovudine | 2006 |
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Oxazines; Prospective Studies; RNA, Viral; Tenofovir; Zidovudine | 2006 |
An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Zidovudine | 2006 |
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; RNA, Messenger; Viral Load; Zidovudine | 2006 |
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Oxazines; RNA, Viral; Tenofovir; Time Factors; Viral Load; Zidovudine | 2006 |
Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Blood Glucose; Body Composition; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Insulin Resistance; Lactic Acid; Lamivudine; Lipids; Male; Reverse Transcriptase Inhibitors; Zidovudine | 2007 |
Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Prospective Studies; Regression Analysis; RNA, Viral; Time Factors; Zidovudine | 2007 |
Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.
Topics: Absorptiometry, Photon; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Composition; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Prospective Studies; Stavudine; Time Factors; Treatment Outcome; United States; Zidovudine | 2007 |
A comparison of three initial antiretroviral AIDS regimens.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; HIV; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 2007 |
144-week data released on Gilead's study 934.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Time Factors; Viral Load; Zidovudine | 2007 |
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
Topics: Adenine; Adult; Alkynes; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2008 |
Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events.
Topics: Adult; Alkynes; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Developing Countries; Dizziness; Drug Tolerance; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; South Africa; Treatment Outcome; Viral Load; Vomiting; Zidovudine | 2008 |
Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure; Treatment Outcome; Zidovudine | 2008 |
Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India.
Topics: Adult; Albumins; Alkynes; Anti-HIV Agents; Antioxidants; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Drugs, Generic; Female; Glutathione Peroxidase; Glutathione Reductase; HIV Infections; Humans; India; Lamivudine; Male; Oxidative Stress; Reverse Transcriptase Inhibitors; Stavudine; Uric Acid; Young Adult; Zidovudine | 2008 |
Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Bacterial Infections; Benzoxazines; Blood Platelets; Cardiovascular Diseases; Cyclopropanes; Deoxycytidine; Didanosine; Emtricitabine; Female; Hemoglobins; HIV Infections; Humans; Leukocyte Count; Male; Middle Aged; Neutrophils; Pancytopenia; Platelet Count; Prevalence; Zidovudine | 2008 |
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Brachial Artery; CD4 Lymphocyte Count; Cyclopropanes; Endothelium, Vascular; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir; Time Factors; Zidovudine | 2008 |
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; DNA, Viral; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Thailand; Treatment Outcome; Zidovudine | 2008 |
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; RNA, Viral; Severity of Illness Index; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Piperazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.
Topics: Absorptiometry, Photon; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Density; Cyclopropanes; Female; HIV Infections; Humans; Inflammation Mediators; Lamivudine; Lopinavir; Male; Middle Aged; Osteoporosis; Prospective Studies; Pyrimidinones; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Risk Factors; Ritonavir; Zidovudine | 2009 |
A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals.
Topics: Adenine; Adipose Tissue; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Extremities; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lipids; Male; Middle Aged; Organophosphonates; Tenofovir; Young Adult; Zidovudine | 2009 |
Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
Topics: Adenine; Alkynes; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genome, Viral; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Mutation, Missense; Organophosphonates; Tenofovir; Treatment Failure; Zidovudine | 2009 |
96-Week MERIT ES analysis shows efficacy of Celsentri=Selzentry.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Cyclopropanes; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Lamivudine; Maraviroc; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome; Triazoles; Zidovudine | 2009 |
Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months.
Topics: Adenine; Adipocytes; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cell Differentiation; Cyclopropanes; Drug Therapy, Combination; Fatty Acids; Female; Gene Expression; Genes, Mitochondrial; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Up-Regulation; Zidovudine | 2009 |
The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Culture; Cyclopropanes; Didanosine; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Surveys and Questionnaires; Zidovudine | 2010 |
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Antiviral Agents; Benzoxazines; CCR5 Receptor Antagonists; Cyclohexanes; Cyclopropanes; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Maraviroc; Middle Aged; Receptors, CCR5; Treatment Outcome; Triazoles; Viral Load; Viral Tropism; Young Adult; Zidovudine | 2010 |
Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Congenital Abnormalities; Cyclopropanes; Female; Humans; Infant; Infant, Newborn; Male; Pregnancy; Pregnancy Complications, Infectious; Prevalence; Young Adult; Zidovudine | 2010 |
Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial.
Topics: Absorptiometry, Photon; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Bone Density; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Pyrimidinones; Ritonavir; Zidovudine | 2011 |
Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Pyridines; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2010 |
A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV; Humans; Lamivudine; Lopinavir; Male; Pyrimidinones; Ritonavir; RNA, Viral; South Africa; Stavudine; Treatment Outcome; Zidovudine | 2010 |
Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Treatment Outcome; Viral Load; Zidovudine | 2011 |
Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Female; Health Knowledge, Attitudes, Practice; HIV Infections; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Organophosphonates; Quality of Life; Tenofovir; Treatment Outcome; Young Adult; Zidovudine | 2011 |
Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis.
Topics: Adult; Alkynes; Anti-HIV Agents; Anti-Inflammatory Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; Cyclopropanes; Dexamethasone; Double-Blind Method; Female; HIV Infections; Humans; Lamivudine; Male; Placebos; Time Factors; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Tuberculosis, Meningeal; Zidovudine | 2011 |
Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cognition; Cognition Disorders; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Zidovudine | 2012 |
Evidence for a shift to anaerobic metabolism in adipose tissue in efavirenz-containing regimens for HIV with different nucleoside backbones.
Topics: Adenine; Adipose Tissue; Adult; Alkynes; Anaerobiosis; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Electron Transport Complex IV; Female; Gene Expression Regulation; HIV Infections; HIV-1; Humans; Ion Channels; Lipogenesis; Male; Middle Aged; Mitochondrial Proteins; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Uncoupling Protein 2; Zidovudine | 2012 |
Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black or African American; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Sex Factors; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2012 |
Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Drug Combinations; Female; Follow-Up Studies; Gambia; HIV Infections; HIV-1; HIV-2; Humans; Infant; Kaplan-Meier Estimate; Lamivudine; Lopinavir; Male; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Zidovudine | 2012 |
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Benzoxazines; Body Fat Distribution; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Young Adult; Zidovudine | 2014 |
Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Body Mass Index; C-Reactive Protein; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Didanosine; Disease Progression; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Multivariate Analysis; Oligopeptides; Prospective Studies; Pyridines; Risk Factors; Selenium; World Health Organization; Zidovudine | 2014 |
Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Nevirapine; Stavudine; Tablets; Uganda; Zambia; Zidovudine | 2016 |
Bleeding patterns of HIV-infected women using an etonogestrel-releasing contraceptive implant and efavirenz-based or lopinavir/ritonavir-based antiretroviral therapy.
Topics: Adolescent; Adult; Alkynes; Amenorrhea; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Desogestrel; Drug Combinations; Drug Implants; Drug Interactions; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Metrorrhagia; Prospective Studies; Ritonavir; Young Adult; Zidovudine | 2016 |
Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Patient Safety; Pregnancy; Primary Prevention; RNA, Viral; South Africa; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies; Viral Load; Zidovudine | 2017 |
Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Composition; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Insulin-Like Growth Factor I; Lamivudine; Male; Prospective Studies; Tenofovir; Zidovudine | 2017 |
Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Biological Variation, Population; Child; Child, Preschool; Cyclopropanes; Drug Monitoring; Female; HIV Infections; Humans; Lamivudine; Male; Tanzania; Zidovudine | 2018 |
Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Outcome Assessment, Health Care; Pregnancy; Pregnancy Complications, Infectious; Raltegravir Potassium; Viral Load; Young Adult; Zidovudine | 2020 |
Brief Report: Vaginal Viral Shedding With Undetectable Plasma HIV Viral Load in Pregnant Women Receiving 2 Different Antiretroviral Regimens: A Randomized Clinical Trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Pregnant Women; Raltegravir Potassium; Vigna; Viral Load; Virus Shedding; Zidovudine | 2021 |
Lower Insulin Sensitivity in Newborns With In Utero HIV and Antiretroviral Exposure Who Are Uninfected in Botswana.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Botswana; Female; HIV Infections; Humans; Infant; Infant, Newborn; Insulin Resistance; Nevirapine; Pregnancy; Zidovudine | 2022 |
226 other study(ies) available for zidovudine and efavirenz
Article | Year |
---|---|
Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.
Topics: Animals; Anti-HIV Agents; Biological Availability; Cell Line; Didanosine; Drug Synergism; HIV Reverse Transcriptase; HIV-1; Humans; Mice; Models, Molecular; Pyridines; Quinoxalines; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship; Thiourea; Zidovudine | 2001 |
Threshold interaction energy of NRTI's (2'-deoxy 3'-substituted nucleosidic analogs of reverse transcriptase inhibitors) to undergo competitive inhibition.
Topics: Anti-HIV Agents; Binding, Competitive; Inhibitory Concentration 50; Models, Molecular; Nucleosides; Protein Binding; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thermodynamics | 2004 |
Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
Topics: Amino Acid Sequence; Animals; Anti-HIV Agents; Binding Sites; Cells, Cultured; Conserved Sequence; Drug Design; Drug Resistance, Viral; Drug Synergism; HIV Reverse Transcriptase; HIV-1; Humans; Macrophages; Mice; Models, Molecular; Mutation; Oxazepines; Pyrroles; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship; Virus Replication; Zidovudine | 2005 |
Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity.
Topics: Anti-HIV Agents; Cell Line; Drug Resistance, Multiple, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Microwaves; Models, Molecular; Mutation; Pyrimidines; Pyrimidinones; Reverse Transcriptase Inhibitors; Solutions; Structure-Activity Relationship | 2005 |
Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.
Topics: Anti-HIV Agents; Binding Sites; Cell Death; Cell Line; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Microwaves; Molecular Structure; Pyrimidines; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship | 2006 |
Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2.
Topics: Anti-HIV Agents; Cell Line; HeLa Cells; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Pyridones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2008 |
Dihydro-alkylthio-benzyl-oxopyrimidines as inhibitors of reverse transcriptase: synthesis and rationalization of the biological data on both wild-type enzyme and relevant clinical mutants.
Topics: Anti-HIV Agents; Cell Line; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Mutation; Pyrimidines; Quantitative Structure-Activity Relationship; Recombinant Proteins; Reverse Transcriptase Inhibitors; Sulfides | 2007 |
Synthesis and biological evaluation of novel 6-substituted 5-alkyl-2-(arylcarbonylmethylthio)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
Topics: Alkylation; Cell Line; HIV-1; Humans; Methylation; Molecular Structure; Nucleosides; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Sulfhydryl Compounds | 2008 |
Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
Topics: Antiviral Agents; Cell Line; Guanine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans | 2008 |
Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
Topics: Anti-HIV Agents; Caco-2 Cells; Cell Line, Tumor; Drug Evaluation, Preclinical; Enzyme-Linked Immunosorbent Assay; HIV; HIV Integrase Inhibitors; Humans; Indoles; Integrases; Molecular Structure; Polymerase Chain Reaction; Viral Proteins; Virus Replication | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Biological Assay; Cell Line; Chemistry, Pharmaceutical; Drug Design; Drug Evaluation, Preclinical; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Chemical; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thiadiazoles; Virus Replication | 2008 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
Topics: Anti-HIV Agents; Conserved Sequence; Drug Resistance; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Mutation; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship | 2009 |
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
Topics: Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Nucleosides; Phenotype; Reverse Transcriptase Inhibitors | 2009 |
Synthesis and biological evaluation of N4-(hetero)arylsulfonylquinoxalinones as HIV-1 reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; HIV Reverse Transcriptase; Quinoxalines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2009 |
Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
Topics: Acetamides; Anti-HIV Agents; Cell Line; HIV Infections; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Models, Molecular; Protein Binding; Structure-Activity Relationship | 2009 |
Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
Topics: Acetanilides; Anti-HIV Agents; Binding Sites; Computer Simulation; HIV Reverse Transcriptase; Humans; Imidazoles; Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutagenesis, Site-Directed; Mutation; Nucleosides; Phenotype; pol Gene Products, Human Immunodeficiency Virus; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Virus Replication | 2010 |
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
Topics: Cell Line; Cell Line, Tumor; Crystallography, X-Ray; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutagenesis, Site-Directed; Nitriles; Pyrazoles; Reverse Transcriptase Inhibitors | 2010 |
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
Topics: Adenine; Anti-HIV Agents; Cell Line; HeLa Cells; HIV-1; Humans; Integrase Inhibitors; Organophosphonates; Pyrrolidinones; Quinolones; Raltegravir Potassium; Tenofovir; Zidovudine | 2011 |
Lindenane disesquiterpenoids with anti-HIV-1 activity from Chloranthus japonicus.
Topics: Anti-HIV Agents; Crystallography, X-Ray; HIV-1; Humans; Magnoliopsida; Molecular Conformation; Molecular Structure; Sesquiterpenes; Structure-Activity Relationship | 2011 |
Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Cell Line, Tumor; Crystallography, X-Ray; Dose-Response Relationship, Drug; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyrimidinones; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship; Virus Replication | 2011 |
Synthesis of new 2'-deoxy-2'-fluoro-4'-azido nucleoside analogues as potent anti-HIV agents.
Topics: Anti-HIV Agents; Cell Line; Crystallography, X-Ray; Cytarabine; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Mass Spectrometry; Models, Molecular; Nucleosides; Spectrophotometry, Infrared | 2011 |
Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.
Topics: Aniline Compounds; Cell Line; Chlorine; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2011 |
Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
Topics: Acetamides; Anti-HIV Agents; Cell Line; HIV Infections; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazoles; Virus Replication | 2011 |
Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.
Topics: Anti-HIV Agents; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2011 |
Library-based discovery and characterization of daphnane diterpenes as potent and selective HIV inhibitors in Daphne gnidium.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Daphne; Diterpenes; Heterocyclic Compounds, 4 or More Rings; Mediterranean Region; Molecular Structure; Receptors, CXCR4 | 2012 |
Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Cell Line; Chemistry Techniques, Synthetic; HIV Reverse Transcriptase; HIV-1; Inhibitory Concentration 50; Piperidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazines | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors.
Topics: HIV Reverse Transcriptase; HIV-1; HIV-2; Models, Molecular; Protein Conformation; Pyrimidines; Reverse Transcriptase Inhibitors; Stereoisomerism | 2012 |
Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.
Topics: Amines; Anti-HIV Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Piperidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazines | 2012 |
Diverse combinatorial design, synthesis and in vitro evaluation of new HEPT analogues as potential non-nucleoside HIV-1 reverse transcription inhibitors.
Topics: Cell Line; Chemistry Techniques, Synthetic; Combinatorial Chemistry Techniques; Drug Design; HIV Reverse Transcriptase; HIV-1; Reverse Transcriptase Inhibitors; Thymine | 2012 |
New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
Topics: Cell Line; HIV Reverse Transcriptase; HIV-1; Indoles; Mutation; Nitrogen; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Sulfones | 2012 |
Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.
Topics: Acetanilides; Anti-HIV Agents; Cell Line; Dose-Response Relationship, Drug; Drug Design; HIV-1; Humans; Imidazoles; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Virus Replication | 2012 |
Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
Topics: Binding Sites; Cell Line; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thioglycolates; Triazines | 2012 |
Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Structure-Activity Relationship; Thioacetamide | 2012 |
Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Benzophenones; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2013 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
Topics: Binding Sites; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Protein Binding; Protein Structure, Tertiary; Pyrimidines; Pyrimidinones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2013 |
Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs.
Topics: Aniline Compounds; Anti-HIV Agents; Drug Design; HIV-1; Humans; Models, Molecular; Piperidines; Structure-Activity Relationship | 2014 |
Phenylspirodrimanes with anti-HIV activity from the sponge-derived fungus Stachybotrys chartarum MXH-X73.
Topics: Animals; Anti-HIV Agents; HIV-1; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Polycyclic Sesquiterpenes; Porifera; Reverse Transcriptase Inhibitors; Sesquiterpenes; Spiro Compounds; Stachybotrys; Structure-Activity Relationship | 2013 |
Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach.
Topics: Cell Line; Drug Discovery; HIV Reverse Transcriptase; HIV-1; Humans; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Pyridines; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship; Virus Replication | 2014 |
Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors.
Topics: Binding Sites; Cell Line; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Protein Structure, Tertiary; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2014 |
New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
Topics: Cell Line; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Inhibitory Concentration 50; Models, Molecular; Protein Conformation; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Sulfones | 2014 |
Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Benzamides; Cell Survival; Cells, Cultured; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Nitriles; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured; Virus Replication | 2014 |
Synthesis of novel fluoro analogues of MKC442 as microbicides.
Topics: Anti-HIV Agents; Cell Line; Drug Resistance, Viral; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Pyrimidinones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Uracil | 2014 |
Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; HIV-2; Microbial Sensitivity Tests; Molecular Structure; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2014 |
2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
Topics: Drug Design; Drug Resistance, Viral; HEK293 Cells; HIV Reverse Transcriptase; HIV-1; Humans; Inhibitory Concentration 50; Models, Molecular; Mutation; Protein Conformation; Quantitative Structure-Activity Relationship; Reverse Transcriptase Inhibitors; Thiazoles | 2014 |
Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
Topics: Anti-HIV Agents; Catalytic Domain; Dose-Response Relationship, Drug; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Molecular Structure; Niacinamide; Protein Conformation; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured | 2014 |
Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Topics: Anti-HIV Agents; Binding Sites; Cell Line; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2015 |
Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
Topics: Anti-HIV Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Nitrogen; Reverse Transcriptase Inhibitors; Solubility; Structure-Activity Relationship; Sulfones | 2015 |
Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.
Topics: Anti-HIV Agents; Chemistry Techniques, Synthetic; Computational Biology; Drug Design; HIV Reverse Transcriptase; HIV-1; Imidazoles; Molecular Docking Simulation; Protein Conformation; Pyrazines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2015 |
Anti-HIV diarylpyrimidine-quinolone hybrids and their mode of action.
Topics: Anti-HIV Agents; Binding Sites; Cell Line; Drug Design; Granulocyte Precursor Cells; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Molecular Docking Simulation; Pyrimidines; Quinolones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tetradecanoylphorbol Acetate; Virus Latency | 2015 |
Pyrazolo-Piperidines Exhibit Dual Inhibition of CCR5/CXCR4 HIV Entry and Reverse Transcriptase.
Topics: | 2015 |
Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
Topics: Anti-HIV Agents; Binding Sites; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Point Mutation; Pyridines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2016 |
Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.
Topics: Anti-HIV Agents; Binding Sites; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Virus Replication | 2016 |
Design, synthesis and anti-HIV-1 evaluation of hydrazide-based peptidomimetics as selective gelatinase inhibitors.
Topics: Anti-HIV Agents; Azides; Drug Design; Gelatinases; HIV-1; Peptidomimetics | 2016 |
1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
Topics: Animals; Antiviral Agents; Cells, Cultured; Dogs; Dose-Response Relationship, Drug; HIV-1; Influenza A Virus, H1N1 Subtype; Madin Darby Canine Kidney Cells; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Uracil | 2016 |
Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
Topics: Anti-HIV Agents; Drug Stability; Esters; HIV-1; Humans; Inhibitory Concentration 50; Methane; Models, Molecular; Reverse Transcriptase Inhibitors | 2016 |
Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.
Topics: Binding Sites; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; Molecular Docking Simulation; Protein Conformation; Pyridines; Pyrimidines; Reverse Transcriptase Inhibitors; Solubility; Structure-Activity Relationship; Water | 2016 |
Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
Topics: Animals; Anti-HIV Agents; Cell Line, Tumor; Drug Resistance, Viral; Heterocyclic Compounds, 2-Ring; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mice; Molecular Docking Simulation; Mutation; Pyrimidines; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Sulfonamides; Thiophenes | 2016 |
Design, synthesis and anti-HIV-1 RT evaluation of 2-(benzyl(4-chlorophenyl)amino)-1-(piperazin-1-yl)ethanone derivatives.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Piperazines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2017 |
Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.
Topics: Animals; Anti-HIV Agents; Cell Line; Drug Discovery; HIV Reverse Transcriptase; HIV-1; Mice; Models, Molecular; Reverse Transcriptase Inhibitors; Solubility; Structure-Activity Relationship; Uracil | 2017 |
Structural modifications of diarylpyrimidines (DAPYs) as HIV-1 NNRTIs: Synthesis, anti-HIV activities and SAR.
Topics: Anti-HIV Agents; Carbon-13 Magnetic Resonance Spectroscopy; HIV-1; Molecular Docking Simulation; Proton Magnetic Resonance Spectroscopy; Pyrimidines; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Electrospray Ionization | 2017 |
Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
Topics: Anti-HIV Agents; Cell Line; Drug Design; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Keto Acids; Molecular Docking Simulation; Pyrimidines; Reverse Transcriptase Inhibitors | 2017 |
Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
Topics: Animals; Anti-HIV Agents; Drug Resistance, Viral; HEK293 Cells; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Pyrimidines; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thiophenes | 2017 |
Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
Topics: Animals; Anti-HIV Agents; Cells, Cultured; Glutamic Acid; HIV-1; Humans; Indoles; Lipopolysaccharides; Mice, Inbred C57BL; Microglia; Molecular Docking Simulation; Mutation; Neurons; Neuroprotective Agents; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship; Sulfones | 2017 |
Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs.
Topics: Anti-HIV Agents; Carbon-13 Magnetic Resonance Spectroscopy; Cell Line; Drug Design; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Proton Magnetic Resonance Spectroscopy; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Electrospray Ionization | 2017 |
Oxazole-Containing Diterpenoids from Cell Cultures of Salvia miltiorrhiza and Their Anti-HIV-1 Activities.
Topics: Anti-HIV Agents; Cell Culture Techniques; Crystallography, X-Ray; Diterpenes; HEK293 Cells; HIV-1; Humans; Oxazoles; Salvia; Salvia miltiorrhiza; Transcription, Genetic | 2017 |
Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
Topics: Anti-HIV Agents; Biphenyl Compounds; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Mutation; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured | 2018 |
The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.
Topics: Allosteric Regulation; Binding Sites; Drug Design; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Molecular Docking Simulation; Protein Structure, Tertiary; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2018 |
Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Niacinamide; Point Mutation; Structure-Activity Relationship; Triazoles | 2018 |
Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the "NNRTI Adjacent" Binding Site.
Topics: | 2018 |
Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.
Topics: | 2018 |
Design, synthesis, docking studies and biological screening of 2-thiazolyl substituted -2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazines as potent HIV-1 reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; HIV Reverse Transcriptase; HIV-1; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Naphthalenes; Oxazines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thiazoles | 2018 |
The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Drug Discovery; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors | 2019 |
Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Design; HIV; HIV Reverse Transcriptase; Humans; Indazoles; Microbial Sensitivity Tests; Molecular Structure; Piperidines; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2020 |
New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
Topics: Anti-HIV Agents; Cell Line, Tumor; Drug Design; Drug Synergism; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Mutation; Protein Binding; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Sulfones; Zidovudine | 2020 |
Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
Topics: Binding Sites; HIV Reverse Transcriptase; HIV-1; Morpholines; Mutation; Pyrimidines; Reverse Transcriptase Inhibitors; Solubility; Structure-Activity Relationship; Water | 2020 |
Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
Topics: Anti-HIV Agents; Binding Sites; Drug Design; HIV-1; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Binding; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2021 |
Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
Topics: Anti-HIV Agents; Drug Design; HIV Reverse Transcriptase; Humans; Molecular Dynamics Simulation; Molecular Structure; Pyrimidines; Structure-Activity Relationship | 2021 |
Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.
Topics: Anti-HIV Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; HIV; HIV Reverse Transcriptase; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2021 |
Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Discovery; HIV Reverse Transcriptase; HIV-1; Humans; Hydrophobic and Hydrophilic Interactions; Microbial Sensitivity Tests; Molecular Structure; Mutation; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2021 |
Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Naphthalenes; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2021 |
Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.
Topics: Anti-HIV Agents; Drug Design; HIV Reverse Transcriptase; HIV-1; Molecular Structure; Reverse Transcriptase Inhibitors; Space Flight; Structure-Activity Relationship | 2022 |
Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
Topics: Animals; Anti-HIV Agents; HIV Reverse Transcriptase; HIV-1; Mice; Molecular Docking Simulation; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2022 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
[HIV infection: DuPont Pharma presents the results of its antiretroviral agent].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Evaluation; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Lamivudine; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viremia; Zidovudine | 1998 |
Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Binding, Competitive; Catalytic Domain; Cyclopropanes; Dideoxynucleotides; Drug Synergism; HIV Reverse Transcriptase; HIV-1; Humans; Kinetics; Oxazines; Reverse Transcriptase Inhibitors; Thymine Nucleotides; Zidovudine | 2000 |
Efavirenz in HIV infection.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Oxazines; Research Design; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 2000 |
Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Arteriosclerosis; Benzoxazines; Cholesterol; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Nevirapine; Oxazines; Risk Factors; Stavudine; Thymidine; Triglycerides; Zidovudine | 2000 |
Efavirenz is a potent nonnucleoside reverse transcriptase inhibitor of HIV type 1 replication in microglia in vitro.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cells, Cultured; Coculture Techniques; Cyclopropanes; HIV-1; Humans; Microglia; Neuroglia; Nucleosides; Oxazines; Reverse Transcriptase Inhibitors; Stavudine; Virus Replication; Zalcitabine; Zidovudine | 2000 |
Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and d- and L-(beta)-dideoxynucleoside triphosphate analogs.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Dideoxynucleotides; DNA Replication; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Synergism; HIV Reverse Transcriptase; Humans; Inhibitory Concentration 50; Mutation; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Stereoisomerism; Thymine Nucleotides; Zidovudine | 2001 |
Dethroning AZT.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Lamivudine; Oxazines; Stavudine; Viral Load; Zidovudine | 1997 |
New drugs on the horizon.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides; United States; Zidovudine | 1998 |
First once-daily drug simplifies dosing, offers new options in HIV-1 treatment.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Oxazines; Patient Compliance; Reverse Transcriptase Inhibitors; Zidovudine | 1998 |
A new approach to initial antiretroviral therapy: protease-sparing combination regimens.
Topics: Alkynes; Anti-HIV Agents; Antineoplastic Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Drugs, Investigational; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxyurea; Lamivudine; Lipodystrophy; Oxazines; Reverse Transcriptase Inhibitors; Time Factors; Zidovudine | 1998 |
A new HAART on the horizon says the proof is in the potency.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Oxazines; Patient Compliance; Pregnancy; Reverse Transcriptase Inhibitors; Zidovudine | 1999 |
New study shows efavirenz effective with d4T and 3TC.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cerebrospinal Fluid; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Oxazines; Reverse Transcriptase Inhibitors; Stavudine; Vagina; Viral Load; Zidovudine | 1999 |
Antiretroviral rounds. When success is a pain.
Topics: Abdominal Pain; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2001 |
Drugs for HIV infection.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dose-Response Relationship, Drug; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Saquinavir; Stavudine; Zidovudine | 2001 |
A case of lipodystrophy after the initiation of zidovudine, lamivudine and efavirenz in an asymptomatic HIV-1-infected patient.
Topics: Abdomen; Adipose Tissue; Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Lipodystrophy; Male; Oxazines; Reverse Transcriptase Inhibitors; Tomography, X-Ray Computed; Zidovudine | 2000 |
Complete remission of AIDS/Kaposi's sarcoma after treatment with a combination of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; HIV-1; Homosexuality, Male; Humans; Lamivudine; Male; Nucleosides; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Sarcoma, Kaposi; Treatment Outcome; Viral Load; Zidovudine | 2002 |
Clinical trials group: two studies are now open to patients who qualify.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Oxazines; Patient Selection; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Viral Load; Zidovudine | 2000 |
Simple rapid method for quantification of antiretrovirals by liquid chromatography-tandem mass-spectrometry.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Calibration; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Evaluation; Gas Chromatography-Mass Spectrometry; Humans; Oxazines; Reproducibility of Results; Sensitivity and Specificity; Stavudine; Zidovudine | 2002 |
Normalization of liver enzymes in an HIV-hepatitis C virus-co-infected patient after potent antiretroviral therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Alanine Transaminase; Alkynes; Anti-HIV Agents; Aspartate Aminotransferases; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C; Humans; Lamivudine; Liver; Oxazines; RNA, Viral; Zidovudine | 2002 |
Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Genetic Variation; Genotype; HIV Reverse Transcriptase; HIV-1; Nevirapine; Oxazines; Phylogeny; Reverse Transcriptase Inhibitors; Zidovudine | 2002 |
When will once (-a day) be enough?
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Didanosine; Emtricitabine; Humans; Hydroxyurea; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Zidovudine | 2000 |
Therapeutic responses to AZT + 3TC + EFV in advanced antiretroviral naive HIV type 1-infected Ugandan patients.
Topics: Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Patient Compliance; Reverse Transcriptase Inhibitors; Uganda; Viral Load; Zidovudine | 2002 |
AIDS drug in halted trial less effective as monotherapy.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Humans; Lamivudine; Oxazines; Viral Load; Zidovudine | 2003 |
[Measuring the HIV viral load with LCx (Abbott): importance for the therapeutic follow-up of 3 patients infected by type O HIV].
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Oxazines; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Viral Load; Viremia; Zidovudine | 2003 |
Recurrence of post-traumatic stress disorder symptoms after initiation of antiretrovirals including efavirenz: a report of two cases.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Male; Middle Aged; Oxazines; Recurrence; Refugees; Reverse Transcriptase Inhibitors; Stress Disorders, Post-Traumatic; Zidovudine | 2003 |
Treatment of primary HIV-1 infection with nonnucleoside reverse transcriptase inhibitor-based therapy is effective and well tolerated.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4-CD8 Ratio; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Flow Cytometry; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Activation; Lymphocyte Subsets; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2004 |
[Ensuring high adherence. Clever combination assures therapeutic success].
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Humans; Lamivudine; Oxazines; Patient Compliance; Randomized Controlled Trials as Topic; Treatment Outcome; Zidovudine | 2003 |
Triple-nucleoside regimens versus efavirenz.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Oxazines; Research Design; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2004 |
Triple-nucleoside regimens versus efavirenz.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Oxazines; Patient Compliance; Reverse Transcriptase Inhibitors; Zidovudine | 2004 |
HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants.
Topics: Acetylcysteine; Alkynes; Antioxidants; Antiretroviral Therapy, Highly Active; Benzoxazines; Cell Adhesion; Cell Adhesion Molecules; Cells, Cultured; Cyclopropanes; Endothelial Cells; Endothelium, Vascular; Gene Expression; Glutathione; Humans; Indinavir; Interleukin-1; Leukocytes, Mononuclear; Nelfinavir; Oxazines; Oxidative Stress; Reactive Oxygen Species; Tumor Necrosis Factor-alpha; Zidovudine | 2004 |
Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Hepatitis; HIV Infections; Humans; Indinavir; Liver Function Tests; Lopinavir; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Zidovudine | 2005 |
Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhib
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Kinetics; Microbial Sensitivity Tests; Models, Molecular; Mutation; Nucleotides; Oxazines; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2005 |
Top stories of 2004. ACTG 5095: efavirenz beats AZT + 3TC + abacavir.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Humans; Lamivudine; Oxazines; Viral Load; Zidovudine | 2005 |
Inhibition of phosphorolysis catalyzed by HIV-1 reverse transcriptase is responsible for the synergy found in combinations of 3'-azido-3'-deoxythymidine with nonnucleoside inhibitors.
Topics: Alkynes; Benzoxazines; Binding Sites; Catalysis; Cyclopropanes; Dideoxynucleotides; DNA Primers; Drug Combinations; Drug Synergism; Enzyme Stability; HIV Reverse Transcriptase; Nevirapine; Oxazines; Phosphoric Acids; Pyridones; Reverse Transcriptase Inhibitors; Templates, Genetic; Thymine Nucleotides; Zidovudine | 2005 |
Rapid viral load suppression following generic highly active antiretroviral therapy in Southern Indian HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drugs, Generic; Female; HIV Infections; HIV-1; Humans; India; Lamivudine; Male; Middle Aged; Oxazines; Prospective Studies; Tablets; Treatment Outcome; Viral Load; Zidovudine | 2005 |
[HIV-1 polymorphism and development of resistance mutations against non-nucleoside reverse transcriptase inhibitor, efavirenz].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV-1; Humans; Mutation; Oxazines; Polymorphism, Genetic; Protease Inhibitors; Reverse Transcriptase Inhibitors; Zidovudine | 2005 |
Recurrence of post-traumatic stress disorder and antiretrovirals.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4-Positive T-Lymphocytes; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Recurrence; RNA, Viral; Stress Disorders, Post-Traumatic; Viral Load; Zidovudine | 2005 |
Genital HIV-1 viral load is correlated with blood plasma HIV-1 viral load in Brazilian women and is reduced by antiretroviral therapy.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Brazil; Cervix Uteri; Cross-Sectional Studies; Cyclopropanes; Female; Genitalia, Female; HIV Infections; HIV-1; Humans; Lamivudine; Longitudinal Studies; Nelfinavir; Prevalence; Time Factors; Vagina; Viral Load; Zidovudine | 2006 |
Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Failure; Treatment Outcome; Viral Load; Zidovudine | 2005 |
Economic impact of antiretroviral therapy prescription decisions in the context of rapid scaling-up of access to treatment: lessons from Mexico.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; Drug Prescriptions; Health Care Costs; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; Humans; Mexico; Oxazines; Patient Compliance; Practice Guidelines as Topic; Saquinavir; Zidovudine | 2006 |
HIV protease inhibitor therapy reverses neutrophil apoptosis in AIDS patients by direct calpain inhibition.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Apoptosis; Benzoxazines; Calpain; Case-Control Studies; Caspase 3; Caspases; Cells, Cultured; Cyclopropanes; Female; HIV Protease Inhibitors; Humans; Indinavir; Kinetics; Leukocytes, Mononuclear; Male; Neutrophils; Oxazines; Proteasome Endopeptidase Complex; Zidovudine | 2006 |
Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Controlled Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Hypersensitivity; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Incidence; Lamivudine; Male; Oxazines; Prospective Studies; Time Factors; Treatment Outcome; Zidovudine | 2006 |
Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol.
Topics: Alkynes; Anti-HIV Agents; Antiviral Agents; Base Sequence; Benzoxazines; Cyclopropanes; Fusion Proteins, gag-pol; HeLa Cells; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Two-Hybrid System Techniques; Virus Replication; Zidovudine | 2006 |
[Effects of traditional Chinese medicine on CD4 + T cell counts and HIV viral loads during structured treatment interruption in highly active antiretroviral therapy].
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Phytotherapy; Time Factors; Treatment Outcome; Viral Load; Zidovudine | 2006 |
Role of antiretroviral treatment in prolonging QTc interval in HIV-positive patients.
Topics: Aged; Alkynes; Benzoxazines; Case-Control Studies; Cyclopropanes; Electrocardiography; Female; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors; Risk Factors; Zidovudine | 2007 |
Report from the XVI International AIDS Conference. Efavirenz for high viral load and low CD4--a secondary analysis of ACTG 5095.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Oxazines; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2006 |
Comparison of the effectiveness of initial combined antiretroviral therapy with nelfinavir or efavirenz at a university-based outpatient service in Brazil.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Clinical Protocols; Cohort Studies; Cyclopropanes; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Retrospective Studies; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2007 |
Prednisolone mediated suppression of HIV-1 viral load strongly correlates with C-C chemokine CCL2: In vivo and in vitro findings.
Topics: Alkynes; Anti-HIV Agents; Anti-Inflammatory Agents; Benzoxazines; Chemokine CCL2; Cyclopropanes; Drug Resistance, Viral; Flow Cytometry; Gene Expression; HIV Infections; HIV-1; Humans; In Vitro Techniques; Interleukin-8; Lamivudine; Male; Prednisolone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Necrosis Factor-alpha; Uveitis; Viral Load; Viremia; Zidovudine | 2007 |
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
Topics: Adenine; Administration, Oral; Adult; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Genitalia, Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2007 |
Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Aspartate Aminotransferases; Benzoxazines; CD4-Positive T-Lymphocytes; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis C; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Linear Models; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Risk Factors; Stavudine; Zidovudine | 2007 |
Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA Repair; HIV Reverse Transcriptase; HIV-1; Humans; Ribonuclease H, Human Immunodeficiency Virus; Zidovudine | 2008 |
Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement.
Topics: Adenine; Adult; AIDS Dementia Complex; Alkynes; Anti-HIV Agents; Anticonvulsants; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cerebrospinal Fluid; Cyclopropanes; Didanosine; HIV-1; Humans; Indinavir; Lamivudine; Male; Nelfinavir; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Seizures; Stavudine; Tenofovir; Viral Load; Virus Replication; Zidovudine | 2008 |
Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cost-Benefit Analysis; Cyclopropanes; Decision Trees; Deoxycytidine; Drug Costs; Emtricitabine; Health Care Costs; Health Resources; HIV Infections; HIV-1; Humans; Lamivudine; Models, Economic; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Zidovudine | 2008 |
[HIV-1 genotypic resistance profiles in children failing highly active antiretroviral therapy].
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; China; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Genotype; HIV-1; Humans; Mutation; Nevirapine; Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Viral Load; Zidovudine | 2007 |
[Evaluation of antiretroviral therapy in HIV-infected adults in the Department of Haematology, University Hospital of Brazzavllle, Congo].
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Congo; Cyclopropanes; Didanosine; Drug Evaluation; Drug Therapy, Combination; Female; Hematology; HIV Infections; Hospital Departments; Hospitals, University; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Retrospective Studies; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2008 |
A case of human bite by an 11-year old HIV positive girl in a paediatrics ward.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Bites, Human; Child; Cyclopropanes; Female; HIV Infections; Humans; Inpatients; Lamivudine; Male; Zidovudine | 2008 |
A prospective study evaluating clinical outcomes and costs of three NNRTI-based HAART regimens in Kerala, India.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; HIV-1; Hospitals, Teaching; Humans; India; Lamivudine; Male; Medication Adherence; Nevirapine; Prospective Studies; Stavudine; Treatment Outcome; Zidovudine | 2009 |
Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Interactions; Glucuronides; Glucuronosyltransferase; Humans; In Vitro Techniques; Indicators and Reagents; Kinetics; Microsomes, Liver; Reverse Transcriptase Inhibitors; Tandem Mass Spectrometry; Zidovudine | 2009 |
[Establishment of pharmacological evaluation system for non-nucleoside reverse-transcriptase inhibitors resistant HIV-1].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Delavirdine; Drug Evaluation, Preclinical; Drug Resistance, Viral; Genetic Vectors; HIV Reverse Transcriptase; HIV-1; Humans; Membrane Glycoproteins; Nevirapine; Plasmids; Point Mutation; Reverse Transcriptase Inhibitors; Stavudine; Transfection; Viral Envelope Proteins; Virion; Virus Replication; Zidovudine | 2009 |
[Tolerance study of a triple first-line antiretroviral combination zidovudine, lamivudine and efavirenz in Dakar, Senegal].
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anemia; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Drug Tolerance; HIV-1; Humans; Lamivudine; Senegal; Zidovudine | 2009 |
Satisfactory cross-cultural validity of the ACTG symptom distress module in HIV-1-infected antiretroviral-naive patients.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cultural Competency; Cyclohexanes; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Language; Male; Maraviroc; Middle Aged; Multicenter Studies as Topic; Psychometrics; Randomized Controlled Trials as Topic; Reproducibility of Results; Stress, Psychological; Surveys and Questionnaires; Triazoles; Zidovudine | 2009 |
Development of an allele-specific PCR for detection of the K65R resistance mutation in patients infected with subtype C human immunodeficiency virus type 1.
Topics: Alkynes; Alleles; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Nevirapine; Polymerase Chain Reaction; Zidovudine | 2010 |
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Proportional Hazards Models; Prospective Studies; Pyridines; Pyrimidinones; Risk Factors; Switzerland; Tenofovir; Zidovudine | 2010 |
Analysis of RT sequences of subtype C HIV-type 1 isolates from indian patients at failure of a first-line treatment according to clinical and/or immunological WHO guidelines.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; India; Lamivudine; Molecular Sequence Data; Nevirapine; Polymorphism, Single Nucleotide; Stavudine; Treatment Failure; Zidovudine | 2010 |
Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Case-Control Studies; Cyclopropanes; Databases, Genetic; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; HIV Reverse Transcriptase; HIV-1; Humans; Logistic Models; Mutation; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Zidovudine | 2010 |
Recent FDA approvals and changes.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Capsules; Cyclopropanes; Dideoxynucleosides; Drug Approval; Drug Labeling; Drugs, Generic; HIV Infections; HIV Protease Inhibitors; Humans; Reverse Transcriptase Inhibitors; Tablets; United States; United States Food and Drug Administration; Zidovudine | 2010 |
Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Multivariate Analysis; Nevirapine; Prospective Studies; Risk Factors; Sex Factors; Stavudine; Uganda; Zidovudine | 2011 |
Evaluating patients for second-line antiretroviral therapy in India: the role of targeted viral load testing.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV; HIV Infections; Humans; India; Lamivudine; Male; Middle Aged; Nevirapine; RNA, Viral; Stavudine; Treatment Failure; Viral Load; Zidovudine | 2010 |
Aminotransferase serum levels decrease after initiating antiretroviral treatment in HIV infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Lopinavir; Male; Pyrimidinones; Ritonavir; Serum; Transaminases; Zidovudine | 2011 |
Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages.
Topics: Alkynes; Benzoxazines; CD4-Positive T-Lymphocytes; Cells, Cultured; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Macrophages; Mutation; Pyrrolidinones; Raltegravir Potassium; Zidovudine | 2011 |
[Comparative study of two anti-antiretroviral protocols used for treatment of a cohort of HIV 1-positive patients followed at the Institute of Public Health and Hygiene in Dakar, Senegal].
Topics: Academies and Institutes; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Seropositivity; HIV-1; Humans; Hygiene; Lamivudine; Nevirapine; Public Health; Quality of Life; Retrospective Studies; Senegal; Survival Analysis; Treatment Outcome; Zidovudine | 2011 |
Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; South Africa; Treatment Failure; Viral Load; Zidovudine | 2011 |
Costs and benefits of multidrug, multidose antiretroviral therapy for prevention of mother-to-child transmission of HIV in the Dominican Republic.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cost-Benefit Analysis; Cyclopropanes; Dominican Republic; Drug Administration Schedule; Drug Costs; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Zidovudine | 2012 |
Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Exanthema; Female; HIV Infections; Humans; Incidence; Lamivudine; Male; Middle Aged; Nevirapine; Nigeria; Organophosphonates; Pain; Retrospective Studies; Risk Factors; Stavudine; Tenofovir; Zidovudine | 2012 |
Response to valacyclovir in an HIV-infected girl with Epstein Barr infection.
Topics: Acyclovir; Alkynes; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; Child; Cyclopropanes; Epstein-Barr Virus Infections; Female; HIV Infections; Humans; Lamivudine; Valacyclovir; Valine; Zidovudine | 2012 |
Monitoring of HAART regime antiretrovirals in serum of acquired immunodeficiency syndrome patients by micellar liquid chromatography.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chromatography, Liquid; Cyclopropanes; Drug Monitoring; Humans; Lamivudine; Organophosphonates; Stavudine; Tenofovir; Zidovudine | 2012 |
In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Didanosine; Dideoxynucleosides; DNA Primers; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Telomerase; Tenofovir; Zidovudine | 2012 |
Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-Retroviral Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Coinfection; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Nevirapine; Nigeria; Organophosphorus Compounds; RNA, Viral; Stavudine; Zidovudine | 2013 |
[A case of vitiligo occurring after initiation of antiretroviral treatment and disappearing during this treatment: autoimmune IRIS syndrome?].
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Follow-Up Studies; HIV Seropositivity; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Male; Viral Load; Vitiligo; Zidovudine | 2012 |
Quantitative analysis of the effect of zidovudine, efavirenz, and ritonavir on insulin aggregation by multivariate curve resolution alternating least squares of infrared spectra.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Humans; Insulin; Kinetics; Least-Squares Analysis; Magnetic Resonance Spectroscopy; Microscopy, Electron, Scanning; Ritonavir; Spectrophotometry, Infrared; Zidovudine | 2013 |
National Guidelines for the prevention of mother-to-child transmission of HIV across Europe - how do countries differ?
Topics: AIDS Serodiagnosis; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Data Collection; Delivery, Obstetric; Europe; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious; Prenatal Care; Surveys and Questionnaires; Zidovudine | 2013 |
Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cyclopropanes; Female; HIV; HIV Infections; Humans; Insulin Resistance; Lamivudine; Male; Middle Aged; Nevirapine; Organophosphonates; Risk Factors; Stavudine; Tenofovir; Triglycerides; Zambia; Zidovudine | 2013 |
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Comorbidity; Cross-Sectional Studies; Cyclopropanes; Diabetes Mellitus; Drug Combinations; Dyslipidemias; Echocardiography; Female; Furans; HIV Infections; Humans; Hypertension; Hypertrophy, Left Ventricular; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphates; Organophosphonates; Risk Factors; Ritonavir; Smoking; Spain; Sulfonamides; Tenofovir; Zidovudine | 2013 |
Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Databases, Factual; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV-1; Humans; Mutation, Missense; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Tenofovir; Zidovudine | 2013 |
Economic evaluation of 3-drug antiretroviral regimens for the prevention of mother-to-child HIV transmission in Thailand.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Health Services; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Models, Econometric; Mothers; Nevirapine; Pregnancy; Thailand; Zidovudine | 2015 |
HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Resistance, Viral; Epidemiological Monitoring; Female; Ghana; HIV Infections; HIV Protease; HIV-1; Humans; Infant; Lamivudine; Male; Middle Aged; Molecular Epidemiology; Molecular Typing; Mutation, Missense; Nevirapine; Prevalence; Sequence Analysis, DNA; Stavudine; Zidovudine | 2013 |
High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa.
Topics: Adolescent; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Nevirapine; Outcome Assessment, Health Care; Prevalence; South Africa; Stavudine; Young Adult; Zidovudine | 2013 |
Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.
Topics: Adult; Alkynes; Area Under Curve; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Pharmacogenetics; Reverse Transcriptase Inhibitors; Treatment Outcome; Uganda; Zidovudine | 2014 |
Hepatitis B and C co-infection among HIV-infected adults while on antiretroviral treatment: long-term survival, CD4 cell count recovery and antiretroviral toxicity in Cambodia.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cambodia; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Female; Hepatitis B; Hepatitis C; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Liver; Logistic Models; Male; Middle Aged; Nevirapine; Proportional Hazards Models; Retrospective Studies; Stavudine; Treatment Outcome; Zidovudine | 2014 |
Challenges of antiretroviral treatment monitoring in rural and remote-access regions in Africa.
Topics: Acquired Immunodeficiency Syndrome; Adult; Africa; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Monitoring; Drug Resistance, Viral; Female; HIV-1; Hospitals, Rural; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Rural Health Services; Rural Population; Stavudine; Treatment Outcome; Zidovudine | 2014 |
Presence of HIV drug resistance in antiretroviral therapy-naive and -experienced patients from Papua New Guinea.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dried Blood Spot Testing; Drug Resistance, Viral; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Papua New Guinea; Reverse Transcriptase Inhibitors; Stavudine; Treatment Failure; Viral Load; Young Adult; Zidovudine | 2014 |
Efavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND).
Topics: Alkynes; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Benzoxazines; Cell Line; Cognition Disorders; Cyclopropanes; Female; HIV Infections; Humans; Lamivudine; Mice; Oxidative Stress; Phagocytosis; Reverse Transcriptase Inhibitors; Zidovudine | 2014 |
MicroRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; CD4 Lymphocyte Count; Cyclopropanes; Disease Progression; Drug Resistance, Viral; Female; Gene Expression Regulation; HIV; Humans; Lamivudine; Leukocytes, Mononuclear; Male; MicroRNAs; Nevirapine; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2014 |
Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.
Topics: Alkynes; Benzoxazines; China; Cyclopropanes; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Nevirapine; Phenotype; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2014 |
Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Female; Health Resources; HIV; HIV Infections; Humans; Lamivudine; Lesotho; Logistic Models; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load; Zidovudine | 2015 |
[Analysis on HIV suppression effect after initiating antiretroviral treatment and related factors among AIDS patients in Henan province during 2008 and 2013].
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; Health Facilities; HIV Infections; Humans; Lamivudine; Male; Nevirapine; Stavudine; Time-to-Treatment; Treatment Outcome; Zidovudine | 2015 |
Time trends of baseline demographics and clinical characteristics of HIV infected children enrolled in care and treatment service in Dar es Salaam, Tanzania.
Topics: Adolescent; Age Distribution; Alkynes; Ambulatory Care Facilities; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Comorbidity; Cyclopropanes; Female; HIV Infections; Humans; Infant; Lamivudine; Linear Models; Male; Nevirapine; Severity of Illness Index; Tanzania; Tuberculosis; Zidovudine | 2015 |
Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Estonia; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Prevalence; Reverse Transcriptase Inhibitors; Zidovudine | 2016 |
Longitudinal Analysis of Adherence to First-Line Antiretroviral Therapy: Evidence of Treatment Sustainability from an Indian HIV Cohort.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; Humans; India; Lamivudine; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2016 |
Anti-HIV-1 activity determined by β-galactosidase activity in the multinuclear activation of an indicator assay is comparable with that by a conventional focus counting method.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; beta-Galactosidase; Cyclopropanes; Dose-Response Relationship, Drug; Genes, Reporter; HeLa Cells; HIV-1; Humans; Microbial Sensitivity Tests; Structure-Activity Relationship; Zidovudine | 2015 |
Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART).
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Case-Control Studies; Cyclopropanes; DNA, Mitochondrial; Drug Combinations; Female; HIV; HIV Infections; Humans; Lamivudine; Lipodystrophy; Lopinavir; Male; Middle Aged; Mitochondria; Nelfinavir; Predictive Value of Tests; Ritonavir; ROC Curve; Stavudine; Zidovudine | 2015 |
[Pharmacokinetic Effect of Aikeqing Granule by Different Medication Ways on Zidovudine in HAART of Rats].
Topics: Alkynes; Animals; Antiretroviral Therapy, Highly Active; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Drugs, Chinese Herbal; Mass Spectrometry; Rats; Zidovudine | 2015 |
CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.
Topics: Adult; Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis; Viral Load; Zidovudine | 2016 |
Theoretical and experimental studies of the stability of drug-drug interact.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Stability; Hydrogen Bonding; Lamivudine; Molecular Docking Simulation; Molecular Dynamics Simulation; Thermodynamics; Zidovudine | 2016 |
HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Coinfection; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; Ethiopia; Female; Genetic Variation; Genome, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Immune Evasion; Lamivudine; Male; Mutation; Stavudine; Viral Load; Zidovudine | 2017 |
Adverse drug reactions associated with antiretroviral therapy in South Africa.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dizziness; Exanthema; Female; Gynecomastia; HIV Infections; Humans; Lipodystrophy; Male; Middle Aged; Nevirapine; Peripheral Nervous System Diseases; Renal Insufficiency; Retrospective Studies; South Africa; Stavudine; Tenofovir; Zidovudine | 2016 |
Improved Adherence to Antiretroviral Therapy Observed Among HIV-Infected Children Whose Caregivers had Positive Beliefs in Medicine in Sub-Saharan Africa.
Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Attitude to Health; Benzoxazines; Caregivers; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; Humans; Infant; Lamivudine; Linear Models; Logistic Models; Male; Medication Adherence; Multivariate Analysis; Nevirapine; Randomized Controlled Trials as Topic; Stavudine; Surveys and Questionnaires; Uganda; Zambia; Zidovudine | 2017 |
Survival Outcomes in a Pediatric Antiretroviral Treatment Cohort in Southern Malawi.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Dideoxynucleotides; Female; HIV Infections; HIV Wasting Syndrome; Humans; Infant; Lamivudine; Malawi; Male; Proportional Hazards Models; Retrospective Studies; Rural Population; Stavudine; Survival Analysis; Tuberculosis, Pulmonary; Zidovudine | 2016 |
Triple Drug Combination of Zidovudine, Efavirenz and Lamivudine Loaded Lactoferrin Nanoparticles: an Effective Nano First-Line Regimen for HIV Therapy.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Benzoxazines; Cell Line, Tumor; Cyclopropanes; Drug Combinations; Female; Half-Life; HIV Infections; HIV-1; Humans; Lactoferrin; Lamivudine; Male; Nanoparticles; Rats; Rats, Wistar; Tissue Distribution; Zidovudine | 2017 |
First-line antiretroviral drug discontinuations in children.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Follow-Up Studies; HIV; HIV Infections; Humans; Infant; Kaplan-Meier Estimate; Lopinavir; Outcome Assessment, Health Care; Proportional Hazards Models; Ritonavir; South Africa; Stavudine; Withholding Treatment; Zidovudine | 2017 |
Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Ethiopia; Female; HIV Infections; Humans; Lamivudine; Male; Models, Theoretical; Nevirapine; Pregnancy; Retrospective Studies; Stavudine; Tenofovir; Time-to-Treatment; Treatment Failure; Zidovudine | 2017 |
Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; HIV-1; Lamivudine; Lopinavir; Nelfinavir; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Ritonavir; Zidovudine | 2017 |
Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Drugs, Generic; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Patient Safety; Poisson Distribution; RNA, Viral; Treatment Outcome; Zidovudine | 2017 |
Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Longitudinal Studies; Male; Mozambique; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2017 |
Central nervous system-penetrating antiretrovirals impair energetic reserve in striatal nerve terminals.
Topics: Adenosine Triphosphate; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cerebral Cortex; Corpus Striatum; Cyclohexanes; Cyclopropanes; Darunavir; Dideoxynucleosides; Dose-Response Relationship, Drug; Emtricitabine; Lopinavir; Male; Maraviroc; Mitochondria; Neurons; Nevirapine; Oxidative Phosphorylation; Permeability; Presynaptic Terminals; Raltegravir Potassium; Rats; Rats, Long-Evans; Triazoles; Zidovudine | 2017 |
Bullseye Retinopathy from Antiretroviral Therapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Humans; Lamivudine; Male; Middle Aged; Retinal Diseases; Reverse Transcriptase Inhibitors; Zidovudine | 2017 |
HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cohort Studies; Coinfection; Cyclopropanes; Female; Hepatitis B; Hepatitis C; HIV; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Retrospective Studies; Treatment Outcome; Viral Load; Zidovudine | 2018 |
Long-term viral suppression and immune recovery during first-line antiretroviral therapy: a study of an HIV-infected adult cohort in Hanoi, Vietnam.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Longitudinal Studies; Male; Middle Aged; Nevirapine; Stavudine; Time Factors; Vietnam; Viral Load; Young Adult; Zidovudine | 2017 |
Different Degrees of Immune Recovery Using Antiretroviral Regimens with Vonavir or Zidovudine/Lamivudine/Efavirenz in HIVPositive Patients Receiving First Line Treatment in Iran.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Immunity, Cellular; Iran; Lamivudine; Male; Retrospective Studies; Reverse Transcriptase Inhibitors; Sex Factors; Time Factors; Zidovudine | 2018 |
A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria.
Topics: Abdominal Pain; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; Humans; Incidence; Lamivudine; Male; Middle Aged; Nausea; Nevirapine; Nigeria; Prospective Studies; Sleep Initiation and Maintenance Disorders; Tenofovir; Young Adult; Zidovudine | 2016 |
Antiretroviral treatment Long-Term (ALT) cohort: a prospective cohort of 10 years of ART-experienced patients in Uganda.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nevirapine; Prospective Studies; RNA, Viral; Time; Uganda; Viral Load; Zidovudine | 2018 |
Comparison of adherence to generic multi-tablet regimens vs. brand multi-tablet and brand single-tablet regimens likely to incorporate generic antiretroviral drugs by breaking or not fixed-dose combinations in HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Drugs, Generic; Female; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Tablets; Viral Load; Zidovudine | 2018 |
Simultaneous quantitation of zidovudine, efavirenz, lopinavir and ritonavir in human hair by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Chromatography, Liquid; Cyclopropanes; Female; Hair; Humans; Limit of Detection; Linear Models; Lopinavir; Male; Medication Adherence; Middle Aged; Reproducibility of Results; Ritonavir; Tandem Mass Spectrometry; Young Adult; Zidovudine | 2018 |
Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cameroon; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Nevirapine; Patient Compliance; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2019 |
Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Incidence; Lamivudine; Male; Middle Aged; Mutation; Nevirapine; Stavudine; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2019 |
Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
Topics: Adolescent; Adult; Age Factors; Albuminuria; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Sex Factors; Tenofovir; Young Adult; Zidovudine | 2020 |
Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Prevalence; Reverse Transcriptase Inhibitors; Taiwan; Zidovudine | 2019 |
HIV Drug Resistance after Failure of 6 Month First-line Therapy in a Hospital: A Case Series.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2019 |
Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Combinations; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Male; Microcephaly; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Puerto Rico; Tenofovir; Young Adult; Zidovudine | 2020 |
Cryptococcal meningitis and immune reconstitution inflammatory syndrome in a pediatric patient with HIV after switching to second line antiretroviral therapy: a case report.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antifungal Agents; Antigens, Fungal; Benzoxazines; Child; Cryptococcus neoformans; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; Fluconazole; HIV; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Lopinavir; Meningitis, Cryptococcal; Ritonavir; Treatment Outcome; Viral Load; Zidovudine | 2020 |
Increased risk of dizziness in human immunodeficiency virus-infected patients taking zidovudine and efavirenz combination: a Brazilian cohort study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Brazil; Cyclopropanes; Depression; Dizziness; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Sleep Initiation and Maintenance Disorders; Survival Analysis; Time Factors; Zidovudine | 2020 |
Influence of a herbal preparation on the pharmacokinetics of highly active antiretroviral therapy drugs in rats.
Topics: Alkynes; Animals; Benzoxazines; Cyclopropanes; Herb-Drug Interactions; Lamivudine; Male; Rats; Zidovudine | 2020 |
Movement disorder in a patient with Human Immunodeficiency Virus on an anti-retroviral therapy: A Case Report.
Topics: AIDS Dementia Complex; Alkynes; Anti-HIV Agents; Benzoxazines; Blood-Brain Barrier; Brain Stem; Cerebellar Ataxia; Cerebellum; Cyclopropanes; Drug Substitution; Female; Gait Ataxia; HIV Infections; Humans; Lamivudine; Magnetic Resonance Imaging; Mesencephalon; Middle Aged; Neurodegenerative Diseases; Nystagmus, Pathologic; Panic Disorder; Pons; Postural Balance; Sensation Disorders; Tenofovir; Zidovudine | 2020 |
Importance of early identification of PrEP breakthrough infections in a generalized HIV epidemic: a case report from a PrEP demonstration project in South Africa.
Topics: Administration, Oral; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Epidemics; Female; HIV Seropositivity; HIV-1; Humans; Lamivudine; Pre-Exposure Prophylaxis; Retrospective Studies; South Africa; Treatment Outcome; Viral Load; Young Adult; Zidovudine | 2020 |
Case report: one case of coronavirus disease 2019 (COVID-19) in a patient co-infected by HIV with a normal CD4
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Betacoronavirus; C-Reactive Protein; CD4 Lymphocyte Count; Chills; Coronavirus Infections; COVID-19; Cyclopropanes; Fatigue; Female; Fever; HIV; HIV Infections; Humans; Immunocompromised Host; Immunoglobulin M; Lamivudine; Middle Aged; Pandemics; Pharyngitis; Pneumonia, Viral; Real-Time Polymerase Chain Reaction; SARS-CoV-2; Sputum; Time Factors; Tomography, X-Ray Computed; Virus Shedding; Zidovudine | 2020 |
Combination of Antiretroviral Drugs Zidovudine and Efavirenz Impairs Tumor Growths in a Mouse Model of Cancer.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antineoplastic Agents; Benzoxazines; Cell Proliferation; Colorectal Neoplasms; Cyclopropanes; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Mice; Mice, Inbred C57BL; Zidovudine | 2021 |